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2 ABBREVIATIONS
ANOVA Analysis of variance
AVDO2 Arterio-venous oxygen diff erence
CT Computer tomography
CP50 Drug concentration associated with 50% of peak drug eff ect   
CNS Central nervous system
CO Cardiac output
CYP450 Cytochrome P 450
EC50 Th e concentration of a drug  required to produce a specifi c eff ect in 50% 
of patients to whom it is administered
EEG Electroencephalography
HR Heart rate
i.v. Intravenous(ly)
MAC Mean alveolar concentration
MAP Mean arterial blood pressure
NMDA N-methyl-D-aspartate
ORL-1 Orphan opioid receptor 
p.o. Peroral(ly)
PaO2 Arterial blood oxygen partial pressure
PaCO2 Arterial blood carbon dioxide partial pressure
P0.1 Airway occlusion pressure at 0.1 seconds
PT Pneumotachometer
RC% Th e proportion of ventilation that can be attributed to rib cage expan-
sion
RIP Respiratory inductive plethysmography
SD Standard deviation
SpO2 Arterial blood hemoglobin oxygen saturation measured by pulse oxim-
etry
TE Expiratory time
TI Inspiratory time
TI/TTOT Inspiratory duty cycle
TTOT Duration of respiratory cycle
TKeo Time of equilibration between serum concentration and eff ect site con-
centration
VA Alveolar ventilation
VAS Visual analogue scale
VCO2 Carbon dioxide production
VE Minute ventilation
10 ABBREVIATIONS
VD Dead space ventilation
VO2 Oxygen consumption
VT Tidal volume
VT/TI Mean inspiratory fl ow
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3  ABSTRACT
Opioids are most commonly used for treatment of severe pain. However, the fear of respi-
ratory depression has restricted the use of opioids. Depending on the monitoring system 
used, diff erent modes of opioid respiratory eff ects have been noted in previous studies. 
All opioids also cause alterations in hemodynamics at least to some extent. Th e main goal 
of this series of investigations was to elucidate the native ventilatory and hemodynamic 
eff ects of diff erent opioids. Also, the eff ects of ketamine were studied in conjunction with 
an opioid causing respiratory depression. In order to avoid the interference of respiratory 
monitoring with the actual drug eff ect, a non-invasive monitoring system was chosen for 
this study. 
Studies I–IV each involved 8 healthy male volunteers. Study V involved 13 patients with 
lower or upper extremity traumas. Th e opioids studied were morphine, oxycodone, pethi-
dine, fentanyl, alfentanil, tramadol and ketamine. Th e respiratory parameters used in this 
study were breathing pattern measured with respiratory inductive plethysmography, gas 
exchange measured with indirect calorimetry, blood gas analysis and pulse oximetry. Hemo-
dynamics was measured with arterial blood pressure, heart rate and oxygen consumption. 
Plasma catecholamine and histamine concentrations were also determined.
All opioids studied caused an alteration in respiratory function. Respiratory rate, alveolar 
ventilation and minute ventilation decreased, while tidal volume increased in most situ-
ations. Breathing pattern was also signifi cantly aff ected aft er opioid administration. Th e 
respiratory depression caused by oxycodone was deeper than the one caused by same 
dose of morphine. An  equianalgesic dose of tramadol caused markedly smaller respira-
tory depression compared to pethidine.  Th e potency ratio for respiratory depression of 
fentanyl and alfentanil is similar to analgesic potency ratio studied elsewhere. Racemic 
ketamine attenuated the respiratory depression caused by fentanyl, if measured with minute 
ventilation. However, this eff ect was counteracted by increased oxygen consumption. Sup-
plemental oxygen did not off er any benefi ts, nor did it cause any atelectasis when given to 
opioid treated trauma patients. 
Morphine caused a transient hemodynamic stimulation, which was accompanied by an 
increase in oxygen consumption. Th is phenomenon was not noted with the use of intra-
venous oxycodone. Alfentanil, fentanyl, tramadol and pethidine infusions had minimal 
eff ects on hemodynamics. Plasma catecholamine concentrations were increased aft er 
morphine, oxycodone and pethidine administration. Plasma histamine concentrations 
were not elevated aft er morphine nor oxycodone administration. 
12 ABSTRACT
Respiratory depression is a side eff ect noted with all opioids. Th e profi le of this phenomenon 
is quite similar with diff erent opioid-receptor agonists. Th e hemodynamic eff ects of opioids 
may vary depending on the opioid used, morphine causing a slight hemodynamic stimula-
tion.  However, all opioids studied could be considered hemodynamically stable. 
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4 INTRODUCTION 
Th e term opioid was originally designated to drugs whose actions resemble morphine. Th is 
defi nition has been broadened to include morphine receptor agonists, as well as antagonists, 
that have a wide spectrum of action on the opioid system. Opioids are most commonly used 
for treatment of severe pain. Opioids exert their actions by binding to specifi c receptors in 
the central nervous system, the most important receptor type being the μ-receptor (Bailey 
et al 2000, Pugsley 2002, Waldhoer et al 2004). Th e most desired action of opioid receptor 
stimulation is analgesia. Also sedation and depression of cough refl ex are usually considered 
benefi cial opioid actions. A signifi cant feature of opioid analgesia is that it is not associated 
with loss of consciousness. However, the fear of side eff ects has restricted the use of opioids, 
the biggest fear being respiratory depression. Th is has occasionally prevented the optimal use 
of opioids in treatment of pain. Respiratory depression caused by opioids has been extensively 
studied in patients, healthy volunteers and animal models (Jordan 1982, McClain et al 1984, 
Bailey et al 2000). A wide range of measurement methods have been used, ranging from 
simple respiratory rate measurement to sophisticated invasive monitoring, such as spirometers 
and pneumotachograms (Jordan 1982). Depending on the monitoring system used, diff erent 
modes of respiratory eff ects have been noted in the previous studies.
Even though the administration of opioids is considered to provide hemodynamic stability, 
all opioids cause alterations to hemodynamics at least to some extent (Pugsley 2002). Th ese 
eff ects have also been studied for decades and results have varied considerably, depending 
on the clinical situation (Kayaalp et al 1966, Zelis et al 1974, Flacke et al 1985, Bailey et al 
2000, Carter et al 2002, Pugsley 2002). In the previous studies, the older opioids morphine 
and pethidine have been shown to cause more changes in hemodynamics than the newer 
ones, i.e., fentanyl and alfentanil. Some of these changes are thought to be mediated by 
histamine release (Bailey et al 2000).
In order to fi nd a potent opioid analgesic with as little side eff ects as possible, diff erent 
opioids have been compared with each other. Mostly, however, all opioids in equianalgesic 
doses produce the same degree of respiratory depression. (Bailey et al 2000). Th e incidence 
of other side eff ects may vary, however. Th e pharmacokinetic and pharmacodynamic profi le 
of diff erent opioids may vary greatly from short acting opioids like alfentanil to longer 
acting opioids, such as morphine and oxycodone. 
Th e main goal of this series of investigations was to elucidate the native ventilatory and 
hemodynamic eff ects of diff erent opioids. Also, the eff ects of ketamine, a non-opioid 
analgesic that produces little respiratory depression, was studied in conjunction with an 
opioid causing respiratory depression. Respiratory monitoring was chosen as non-invasive 
as possible in order to avoid the interference of monitoring with the actual drug eff ect on 
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ventilation. Unlike in many previous studies, opioids and ketamine were given to healthy 
volunteers and trauma patients as a sole medication and thus the eff ects found in these 
studies possibly represent a true opioid action. 
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5 REVIEW OF LITERATURE
5.1 Opioid receptors mediating respiratory depression
All opioids act in the central nervous system by binding to specifi c receptors, defi ned as 
opioid receptors (Table 1.) (Pugsley 2002, Fukuda 2005, Lalovic et al 2006).  Th e activation 
of these receptors induce analgesia, ventilatory depression, sedation, euphoria, dysphoria, 
dizziness, depression of cough refl ex, decreased gastrointestinal motility, nausea, vomiting 
and urinary retention. Th ese eff ects are blocked by specifi c opioid receptor antagonists, 
such as naloxone.
Table 1. Selectivity of opioids at the various opioid-receptor classes.                           
Receptor type
Drug μ δ κ ORL-1
Morphine +++ + + 0
Oxycodone ++ + + 0
Pethidine ++ + + 0
Fentanyl +++ + + 0
Alfentanil +++ + + 0
Tramadol ++ + + 0
Naloxone --- - -- 0
Nociceptin 0 0 0 +
Ketamine + 0 0 0
Agonist: + low, ++ moderate, +++ high affi  nity
Antagonist: - low, -- moderate, --- high affi  nity
0= no affi  nity ORL-1= orphan opioid receptor
Th ere are three major groups of opioid receptors: mu (μ), kappa (κ) and delta (δ). Th ese 
receptors have been further divided into subtypes: μ1, μ2, δ1, δ2, κ1, κ2, and κ3. An additional 
opioid receptor has been recently identifi ed, the ORL-1 receptor (orphan opioid recep-
tor). Its natural ligand is an endogenous peptide called nociceptin (Pugsley 2002). Th e μ-, 
δ- and κ- receptors mediate analgesia with considerable overlap. In the μ-receptor-family, 
analgesia is produced via μ1 (supraspinal) and μ2 (spinal)-receptors. Respiratory depression 
is mediated via μ2-receptor in brainstem, whereas μ1-receptor has been shown to induce 
respiratory stimulation (Bailey et al 2000, Puglsey 2002, Waldhoer 2004). Agonists selective 
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at δ-receptor have also a mild respiratory depressant eff ect, whereas κ-receptor agonists 
produce little, if not at all respiratory depression. Th us, respiratory depression is mainly 
mediated through μ2-receptor. 
Sigma –receptor agonists stimulate ventilation; however, sigma-receptor is not classifi ed 
as an opioid receptor, because sigma-receptor mediated eff ects are not reversed by opioid 
antagonists (Bailey et al 2000, Puglsey 2002, Waldhoer 2004). 
Th e primary eff ect of opioid receptor activation is reduction of neurotransmission. All 
opioid receptors are linked through G proteins to inhibit adenylate cyclase. Th ey also 
facilitate the opening of K+ channels (causing hyperpolarization), and inhibit the opening 
of Ca+ channels (inhibiting transmitter release) (Pugsley 2002).
5.2 Respiratory effects of opioids
Respiratory depression induced by opioids is characterized by dose related, naloxone-re-
versible depression of resting minute ventilation (VE), with decreased PaO2 and increased 
PaCO2. Th e diminution of VE is mostly due to a slower rate of breathing (McClain et al 1984, 
Santiago et al 1985, Bailey et al 2000). Tidal volume (VT) is either reduced or increased aft er 
opioid administration. Th e prolonged expiratory time (VE) in the respiratory cycle induced 
by opioids frequently results in greater reductions in respiratory rate than in VT (Drum-
mond 1983). Opioids may also decrease the metabolic rate and the production of CO2, 
which results in lowered VE (Jordan 1982, McClain et al 1984). Th e primary mechanism of 
respiratory depression induced by opioids involves a reduction in the responsiveness of the 
brainstem respiratory centers to CO2, evidenced as the decrease in the slope and rightward 
shift  of the CO2 response curve (McClain et al 1984, Bailey et al 2000). Also, the apneic 
threshold and resting end-tidal PCO2 are increased by opioids. Th e peripheral chemorecep-
tor responsiveness to hypoxia is reduced with higher opioid doses. Opioids also blunt the 
increase in respiratory drive normally associated with increased loads, such as increased 
airway resistance (Bailey et al 2000). Another respiratory depressant mechanism reported 
with opioid administration is increased muscle rigidity, especially in conjunction with 
rapid administration of short acting opioids, such as fentanyl, alfentanil and remifentanil 
(Bailey et al 2000). In addition, postoperatively administered opioids may cause upper 
airway obstruction by loss of pharyngeal muscle tone (Bailey et al 2000). Th e respiratory 
depression induced by opioids is also potentiated by natural sleep (Jordan 1982).
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5.2.1  Morphine
Most of the opioids in clinical use today are based on the structure of morphine. Morphine 
is a relatively selective μ-agonist, but will also interact with the other opioid receptors (δ, 
κ) at higher concentrations (Table 1). The pharmacokinetics of morphine is determined 
to a major degree by its low lipid solubility. After i.v. administration morphine is rapidly 
distributed, but its tissue penetration is slow due to this low lipid solubility. Slow brain 
penetration means that respiratory depression as well as analgesia are not necessarily re-
fl ected by plasma levels and may occur after a certain time lag, i.e., 10–15 minutes (Bailey 
et al 2000). However, a direct relationship between plasma morphine concentration and 
end-tidal CO2 increase has also been reported (Hill et al 1990). Morphine is metabolized 
mainly to morphine-3-glucuronide (M3G) and less into morphine-6-glucuronide (M6G). 
M6G is a potent μ-receptor agonist with a weaker respiratory depressant action compared 
to morphine (Peat et al 1991, Thompson et al 1995).
 Th e ventilatory eff ects of morphine have been studied both in patients and healthy vol-
unteers. When 0.12–0.15 mg of morphine was given as an i.v. bolus to healthy volunteers 
breathing room air, it resulted in signifi cant decrease in respiratory rate and VE with an 
increase in PaCO2 or end-tidal CO2 (Rigg et al 1981, Peat et al 1991, Th omson et al 1995). 
Th e ventilatory response to CO2 was also reduced together with mean inspiratory fl ow 
(VT/TI). VT was not aff ected to the same degree as respiratory rate. When 10 mg of morphine 
was given to patients prior to anesthesia, similar eff ects were noted; decrease of respiratory 
rate, VT and VE. Th e decrease in respiratory rate and VE persisted for up to 20–40 minutes, 
whereas the decrease in VT was transient and later on changed to an enhancement of VT 
(Orkin et al 1955). A decrease in respiratory rate and increase in VT has also been reported 
in intensive care unit patients given 10 mg/70 kg of morphine. (Samuel et al 1977). Morphine 
administration of 10 mg/70 kg has been shown to decrease oxygen consumption (VO2), 
measured with tidal pneumotachograph, when given to healthy volunteers breathing room 
air (Jennett et al 1968).
5.2.2  Oxycodone
Oxycodone resembles morphine in many respects, it is a synthetic derivative of thebaine 
and a selective μ-agonist (Brittain 1959, Lalovic et al 2006). It is metabolized to oxymor-
phone and noroxycodone, which are conjugated and exerted in urine. Th e equianalgesic 
dose ratio of oxycodone and morphine in earlier studies of postoperative patients varies 
from 1:1 (Brittain 1959, Silvasti et al 1998) to 2:3 (Kalso et al 1991). Th e clinical potency 
of oxycodone exceeds that of morphine, even though the μ-receptor binding affi  nity of 
oxycodone is lower than morphine. However, the blood-brain barrier penetration of 
oxycodone is higher than that of morphine (Lalovic et al 2006.) Th e lipid solubility of 
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oxycodone is suggested to be close to that of morphine (Pöyhiä et al 1994). However, the 
onset of analgesia and respiratory depression is faster with oxycodone than morphine. 
Th is might explain the deeper respiratory depression reported with oxycodone compared 
to morphine or pethidine (Takki et al 1973, Kalso et al 1991). In the postoperative phase 
0.1 mg/kg oxycodone resulted in increase of end-tidal CO2 by 0.6%, whereas 0.2 mg/kg 
increased end-tidal CO2 by 1.0%, with a deeper dose-response curve than with pethidine 
(Takki et al 1973). Also in children, deeper respiratory depression aft er oxycodone than 
aft er other opioids has been reported (Olkkola et al 1994). However, the more profound 
respiratory depression aft er oxycodone compared that aft er morphine has not been verifi ed 
in all studies (Silvasti et al 1998).
 5.2.3  Pethidine
Pethidine (meperidine) is a derivative of phenylpiperidine and a predominantly μ-receptor 
agonist; however, its μ-receptor binding affi  nity is slightly weaker than that of morphine. 
Th e potency of pethidine is approximately 1:7 to 1:10 compared to that of morphine. In 
equianalgesic doses, pethidine predominantly produces as much respiratory depression 
as does morphine. When given preoperatively to patients, 100 mg/70 kg intravenous 
pethidine decreases VE and VT, but increases the respiratory rate (Orkin et al 1955). In the 
postoperative phase, pethidine produces a slight (Muneyuki et al 1969, Welchew et al 1985) 
reduction or no eff ect at all (Keats et al 1968) on the respiratory rate, with a decrease in VE 
and increase in PaCO2. In children, the acute respiratory depression produced by pethidine 
is reported to be steeper but of shorter duration than that of morphine (Hamunen 1993). 
Subcutaneous infusion of 20 mg/h pethidine in the postoperative phase in adults does 
not seem to produce noticeable respiratory depression, when measured with respiratory 
rate (Davenport et al 1985). Pethidine is metabolized into norpethidine, which also has 
analgesic eff ects but is a potential convulsant (Bailey et al 2000).
5.2.4  Fentanyl
Fentanyl is a synthetic derivative of phenylpiperidine with faster onset and duration of ac-
tion than pethidine. Th e analgesic onset time of intravenous fentanyl is about 1.5 minutes 
and the time to peak eff ect is 3.6–4.5 minutes. High lipid solubility and low plasma protein 
binding result in a large distribution volume (4.0 l/kg) (McClain et al 1980 , Shafer et al 
1991, Scholz et al 1996). Th e fi rst pass uptake of fentanyl by lung tissue is up to 75% aft er an 
intravenous injection (Roerig et al 1987). Th e plasma fentanyl concentration decay is usually 
described by a three-compartment model, with plasma clearance of 10–20 ml/kg/min. TKeo 
of eff ect site concentration is 4.7–6.9 minutes (Scott et al 1985, Scott et al 1987, Ebling et al 
1990). Th e mean eff ective analgesic plasma concentrations of fentanyl are approximately 1 
and 3 ng/ml, respectively for postoperative and intraoperative administration. Th e CP50 for 
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fentanyl at surgical skin incision with 70% N2O is estimated to vary from 3.26 to 4.17 ng/ml 
(Glass et al 1993) and for experimental pain produced by dental pulp stimulation 1.3–1.8 
ng/ml (Hill et al 1990). Ventilatory depression produced by fentanyl occurs at a CP50 of 
2.0–3.1 ng/ml, when measured postoperatively in surgical patients with CO2 responsive-
ness (Cartwright et al 1983). Aft er a single bolus administration on healthy volunteers, 
the EC50 for respiratory depression is reported to be 4.6 ng/ml (Fung et al 1980). Adequate 
ventilation on recovery of anesthesia is possible when concentrations decrease to 1.5–2.9 
ng/ml (Clotz et al 1991, Shaefer et al 1991). Rapid bolus administration of fentanyl can 
be associated with muscle rigidity, especially when doses high enough to produce loss of 
consciousness are used (McClain et al 1984, White et al 1986, Neidhart et al 1989). 
5.2.5  Alfentanil
Alfentanil is a synthetic derivative of phenylpiperidine. Th e high amount of non-ionized 
molecules of alfentanil at the physiological pH of 7.4 results in a very short onset time (0.75 
min) and time to peak eff ect (1.4–1.5 min), because most of the drug can pass the blood-
brain barrier (Shafer et al 1991, Scholz et al 1996). TKeo of alfentanils eff ect site concentration 
at the CNS is 0.9–1.1 min (Scott et al 1985, Scott et al 1987, Ebling et al 1990). Alfentanil 
is less lipid soluble than fentanyl, but more lipid soluble than morphine. Th e plasma clear-
ance of alfentanil is less than that of fentanyl, approximately 6.4 ml/kg/min, and the steady 
state volume of distribution is 0.75–0.86 l/kg. Alfentanil is faster and shorter acting than 
fentanyl. Th e mean eff ective plasma concentration of alfentanil during surgery is between 
250–350 ng/ml (Ausems et al 1986). Th e CP50 of alfentanil for surgical skin incision associ-
ated with the use of 70% N2O is 240 ng/ml and the alfentanil concentration required for 
recovery of spontaneous ventilation aft er general surgery varies between 125–226 ng/ml 
(Ausems et al 1986, Clozt et al 1991, Shafer et al 1991). Th e EC50 of alfentanil for ventilatory 
depression during target controlled infusion in healthy volunteers is 49–60 ng/ml, when 
measured as VE response to 7.5% CO2. As well as with fentanyl, muscle rigidity produced 
by alfentanil is most oft en associated with bolus administration and is best treated with 
muscle relaxants (Benthuysen et al 1986, White et al 1986). Muscle rigidity in conjunc-
tion with a high alfentanil bolus can be associated with decreased arterial oxygen tension 
(Benthuysen et al 1986).
Th e relative potency of fentanyl and alfentanil at steady-state plasma concentrations has 
been verifi ed mainly by three diff erent methods. First, the ability of these drugs to reduce 
the MAC of isofl urane gives a potency ratio of 1:58 of alfentanil:fentanyl, respectively (Glass 
et al 1993, Westmoreland et al 1994). When using the slowing of EEG as a determinant 
of drug action, the relative potency of alfetanil and fentanyl varies between 1:66–1:70. 
(Ebling et al 1990, Gambus et al 1995, Scott et al 1985). Th e ability of these drugs to pro-
duce analgesia either during surgical procedure or during experimental pain condition, 
reveals the potency ratio of 1:40–1:58 (Hill et al 1990, Scott et al 1987). Th e potency ratio 
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for respiratory depression measured with steady-state plasma concentrations, however, 
has not been properly determined,.
5.2.6  Tramadol
Tramadol is a synthetic opioid of the aminocyclohexanol group. It is a moderately weak 
μ-agonist. It also enhances the function of the spinal descending inhibitory pathways by 
inhibition of reuptake of both norepinephrine and 5-hydroxytryptamine (5-HT) together 
with presynaptic stimulation of 5-HT release (Kayser et al 1992, Lee et al 1993, Desmeules 
et al 1996). Th e currently used tramadol is a racemic 1:1 mixture of (+)-tramadol and (-)-
tramadol. Th e opioid receptor eff ects are mainly mediated by the (+)-enantiomer and the 
monoaminergic eff ects by (-)-enantiomer (Grond et al 1995). Tramadol is metabolized by 
the cytochrome P450 enzyme system in liver and the metabolite M1 of (+)-tramadol has 
higher affi  nity to μ-receptor than the parent compound itself. Th e potency of tramadol 
is oft en referred to be equianalgesic or slightly weaker compared to that of pethidine, 
when measured on mg to mg basis. When compared to morphine, the effi  cacy ratio is 
close to 10:1 (Vickers et al 1992, Lee et al 1993, Lehmann 1994). Th e respiratory eff ects 
produced by intravenous tramadol are oft en referred to be minimal when compared to 
other μ-agonists. Th is is probably due to moderately weak μ-receptor actions of tramadol. 
However, 1.0–1.5 mg/kg of intravenous tramadol has been shown to decrease the mouth 
occlusion pressure and minute volume response to CO2 up to 25% (Seitz et al 1985). 
When comparing intravenous injections of tramadol 0.5, 1 and 2 mg/ml, a dose-response 
relationship was found only for respiratory rate, but not for end-tidal CO2 or VE (Vickers 
et al 1992). When comparing tramadol and pethidine during inhalation of 70% N2O and 
0.3% halothane, 0.6 mg/kg tramadol did not induce any respiratory depression, whereas 
0.6 mg/kg pethidine caused a signifi cant reduction in respiratory rate and minute volume 
(Tarkkila et al 1998).
5.3  Hemodynamic effects of opioids
In addition to pain relief, opioids are administered in order to suppress or block the 
hemodynamic stimulation induced by pain or surgery. However, in the absence of pain, 
opioids themselves may have some eff ects on hemodynamics, the most common of these 
being bradycardia. Opioid receptors are widely distributed in those regions of CNS which 
mediate various hemodynamic responses, i.e., nucleus solitarius, the dorsal vagal nucleus, 
the nucleus ambiguus and the parabrachial nucleus. Th e direct administration of μ-ago-
nists into the CNS most commonly produces hypotension and bradycardia. Most opioids 
reduce sympathetic and enhance parasympathetic tone, which also predisposes a patient 
to bradycardia and hypotension. (Bailey et al 2000, Carter et al 2002). During anesthesia, 
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opioids also exert an antiarrhythmic action (Bailey et al 2000). Th e hemodynamic eff ects 
of opioids have widely been studied previously. 
Table 2. Hemodynamic eff ects of opioids
Opioid Source Dose Eff ect on 
HR
Eff ect 
on MAP
Other eff ects
Morphine Kayaalp et al 1966 
Lowenstein et al 1969
Zelis et al 1974
Vatner et al 1975
Rosow et al 1982
Fahmy et al 1983
Pfeiff er et al 1983
Flacke et al 1985
Muldoon et al 1987
Warner et al 1991
Withington et al 1993
Doenicke et al 1995
Grossman et al 1996
Carter et al  2002
1–4 mg/kg (cats) 
1 mg/kg
15 mg 
2 mg/kg (dogs)
1 mg/kg
0.3 mg/kg
Encephalin (rats)
0.6 mg/kg
3 mg/kg
1 mg/kg
0.16 mg/kg
0.15 mg/kg
Diff erent doses
0.075 mg/kg
Increase
Decrease
NDA
Increase
0
Increase
Increase
0
Increase
NDA
0
0
NDA
Decrease
Increase
0
0
0
Decrease
Decrease
Increase
Decrease
Decrease
0
0
0
Increase
Increase
No change in SVR
Venoconstriction
Decrease in SVR
Decrease in SVR
No change in SVR
Venodilatation
Increase in MSNA
Oxycodone Takki et al 1973
Kalso et al 1991
Pöyhiä et al 1992
0.1–0.2 mg/kg 
21.8 ± 2.9 mg/kg 
0.28 mg/kg
0
Decrease
Decrease
0
Decrease 
0
Pethidine Takki et al 1973
Flacke et al 1985
Bailey et al 2000
0.5–1.0 mg/kg
4.3 ± 0.2 mg/kg 
Diff erent doses
Increase
Increase
Increase
0
Decrease 
NDA Negative inotrope
Fentanyl McClain et al 1980
Scott et al 1983
Neidhart et al 1989
Bailey et al 2000
3.2–6.4 μg/kg 
717 ± 414 μg
21 μg/kg 
Diff erent doses
Increase
0
NDA 
0
Increase
0
Decrease 
0
Alfentanil McDonnel et al 1984
Benthuysen et al 1986
Ausems et al 1988
Bailey et al 2000
100–250 μg/kg
175 μg/kg 
10 mg
Diff erent doses
Increase 
Increase 
Decrease
Decrease
0
Decrease
Decrease 
0
Muscle rigidity
Tramadol Chrubasik et al 1992
Lee et al 1993
Radbruch et al 1996
100–150 mg 
0.75–1.5 mg/kg 
Diff erent doses
0
Increase 
0
NDA 
Increase 
0
NDA= no data available   SVR= systemic vascular resistance   
MSNA=muscle sympathetic nerve activity 0 = no eff ect
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5.3.1  Morphine
Morphine produces various hemodynamic changes, which are thought to be mediated by 
histamine release. Th e most frequent hemodynamic eff ect of morphine is the reduction of 
peripheral vascular resistance and baroreceptor refl ex activity, resulting in peripheral vasodila-
tation and hypotension. Th ese eff ects are most evident aft er large doses, or in patients with 
volume depletion, or in other forms of hypotension. Morphine 0.6 mg/kg induces tachycardia 
and hypotension when given during general anesthesia (Flacke et al 1985), whereas 0.15 
mg/kg of morphine does not seem to have any eff ect at all on the hemodynamics of healthy 
volunteers (Doenicke et al 1995). Peripheral venodilatation induced by morphine is only 
partly antagonized by naloxone, which speaks in favor of non-opioid regulated vasodilatory 
mechanism (Grossman et al 1996). Th e vasodilatation induced by 15 mg intravenous mor-
phine is possibly preceded by transient venoconstriction (Zelis et al 1974). A chronotropic 
eff ect of morphine can also be mediated by the release of catecholamines (Fahmy et al 1983, 
Muldoon et al 1987). In animal studies morphine has been shown to induce hypertension and 
tachycardia when given as a sole medication. However, when morphine administration was 
combined with β-blocking or anesthetic agents, this pressor refl ex is changed to hypotension 
and tachycardia. (Kayaalp et al 1966, Vatner et al 1975, Pfeiff er et al 1983).
5.3.2  Oxycodone
Th e eff ects of oxycodone on hemodynamics are not widely studied. When given orally to 
healthy volunteers, 0.28 mg/kg of oxycodone decreased HR, but did not have any eff ect on 
MAP (Pöyhiä et al 1992). In the postoperative phase, a reduction of HR and blood pressure 
was achieved similarly aft er oxycodone and morphine administration (Kalso et al 1991). 
When compared to equianalgesic doses of pethidine and piritramide in the postoperative 
phase, hemodynamics remained more stable aft er oxycodone administration than aft er 
the others (Takki et al 1973).
5.3.3  Pethidine
When given i.v., pethidine commonly causes tachycardia. Th is may be related to its struc-
tural similarity to atropine or to the eff ect of norpethidine as an early manifestation of 
its toxic CNS eff ects.(Bailey et al 2000). Pethidine is reported to liberate histamine, even 
to a greater degree than morphine, which can also contribute to the cronotropic eff ect 
of pethidine. (Flacke et al 1987).  Hypotension can result aft er pethidine administration. 
Pethidine itself is reported to have at least some degree of negative inotropic eff ects on 
myocardium (Bailey et al 2000).
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5.3.4  Fentanyl
Th e eff ect of fentanyl on hemodynamics is minimal. It produces little or no change in most 
hemodynamic variables, i.e. HR, MAP, CO, even aft er large doses. (Bailey et al 2000). Plasma 
fentanyl concentrations adequate to produce slowing of EEG, i.e. 6.9 ng/ml do not aff ect 
hemodynamics (Scott et al 1985). Th e most frequent eff ect of fentanyl on hemodynamics is 
slight bradycardia, an eff ect of μ-agonists. However, in healthy subjects, 3.2 to 6.4 μg/kg of 
fentanyl can cause increases in blood pressure and HR, which are preceded by hypercarbia 
(McClain et al 1980). A decrease in MAP has also been reported with 21 μg/kg of fentanyl 
(Neidhart et al 1989).
5.3.5  Alfentanil
Alfentanil resembles fentanyl in the hemodynamic responses, which have been found to 
be minimal. Similarly to fentanyl, the plasma alfentanil concentrations adequate to pro-
duce slowing of EEG (520 ng/ml) and loss of consciousness (1012 ng/ml), preserve stable 
hemodynamics. However, there is evidence that alfentanil produces more hypotension and 
myocardial ischemia compared to fentanyl, when given during coronary surgery (Bailey et al 
2000). An i.v. bolus of 10 mg alfentanil given at the induction of general anesthesia induced 
hemodynamic changes, hypotension and bradycardia, more oft en than a continuous, target 
controlled, computer-assisted i.v. infusion of the same dose (Ausems et al 1988). Muscle 
rigidity, which is oft en related to large intravenous bolus doses of alfentanil, is associated 
with decreases in MAP and increases in HR (Benthuysen et al 1986).
5.3.6  Tramadol
Th e eff ect of tramadol on hemodynamics is reported to be minimal, and no clinically 
relevant changes in heart rate or blood pressure were observed in the study of Radbruch et 
al (1996). On the other hand, Lee et al (1993) reported a slight and clinically insignifi cant 
increase in MAP and HR aft er 0.75 to 1.5 mg/kg intravenous doses of tramadol.
5.4.  Histamine release by opioids
Th e opioids most frequently reported to release histamine are pethidine and morphine 
(Flacke et al 1987). Th e histamine-liberating action of morphine has been shown by Philbin 
et al (1981), who administered morphine in conjunction with both H1 and H2 –receptor 
blocking agents. Th ey found a signifi cant increase in plasma histamine concentration aft er 
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1 mg/kg of morphine. Th is was associated with a decrease in diastolic blood pressure and 
systemic vascular resistance. Th ese hemodynamic eff ects were prevented by co-administra-
tion of both H1- and H2 –blocking agents. Th is histamine liberating action of morphine has 
been confi rmed by other authors as well (Rosow et al 1982, Moss et al 1983, Flacke et al 
1987, Muldoon et al 1987, Withington et al 1993, Doenicke et al 1995). However, Warner 
et al (1991) have challenged these results by repeating the original study of Rosow et al 
(1982) with 1 mg/kg of morphine, and using more novel histamine assays, i.e. double-
isotope radioenzymatic technique instead of single-isotope radioenzymatic assay as used 
by Rosow et al (1982). Th ey found no increase in plasma histamine levels aft er morphine, 
as well as no change in hemodynamics (Warner et al 1991). However, the present opinion, 
which is mainly based on the studies by Rosow (1982), Flacke (1987), Muldoon (1987), 
Withington (1993) and Doenicke (1995), is that the clinically used doses of morphine 
cause a variable degree of histamine release.
Th e ability of oxycodone to liberate histamine appears to be minimal (Pöyhiä et al 1992, 
2004). However, there may be considerable diff erences in species in this regard because 
oxycodone is reported to release histamine from porcine mast cells, even in higher amounts 
than morphine (Ennis et al 1991).
Histamine liberation of cutaneous mast cells produces local wheal and fl are responses and 
possibly adverse hemodynamic eff ects (Hermens et al 1985, Levy et al 1989). Th ese cutane-
ous wheal and fl are responses aft er morphine and pethidine administration were similar 
to those aft er histamine and were not antagonized by naloxone. Unlike alfentanil, fentanyl 
is capable of producing wheal and fl are responses, but these eff ects were antagonized by 
naloxone and were thought to be a result of a direct vasodilatory eff ect (Levy et al 1989). 
A rise in plasma histamine concentrations to 1.6 to 2.4 ng/ml seems to be needed for 
eliciting symptoms (Kaliner et al 1982). Th e clinical symptoms produced by these plasma 
concentrations are predominantly tachycardia and increase in pulse pressure. 
5.5  Catecholamine release by opioids
While one of the rationales of opioid use is the prevention of stress responses, increases in 
catecholamine concentration has been shown aft er opioid administration. Fentanyl 0.1–0.25 
mg/70 kg as well as morphine 10mg/70 kg given to healthy volunteers, resulted in dose-
dependent increase in plasma norepinephrine concentrations, whereas plasma epinephrine 
levels were increased only with lower fentanyl doses (Hoeche et al 1993). Th is action of 
opioids is thought to be mediated by μ- as well as κ-receptors. Both morphine and pethidine 
administration can be accompanied by catecholamine release (Taborsky et al 1981, Fahmy 
et al 1983, Flacke et al 1985, Muldoon et al 1987). Th is release of epinephrine is also thought 
to be secondary to histamine release (Fahmy et al 1983, Muldoon et al 1987).
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5.6  Other opioids
Other opioids from the phenylpiperidine group that are frequently used are sufentanil 
and remifentanil. Sufentanil resembles fentanyl, with similar TKeo of eff ect site, i.e.,  6.5 
min (Fukuda 2005, Lötsh 2005a). However, sufentanil has a 12-fold greater potency than 
fentanyl shift ing the EEG spectral edge to the left . Remifentanil is a very short-acting opioid, 
with a high plasma clearance by de-esterifi cation via blood esterases. Also, the steady-state 
distribution volume of remifentanil is small. TKeo of eff ect site for remifentanil resembles that 
of alfentanil, i.e., 1.6 min. (Fukuda 2005, Lötsh 2005a), but remifentanil is 19 times more 
potent than alfentanil in slowing down EEG. Despite its unique pharmacokinetic profi le, 
the pharmacodynamic eff ects of remifentanil parallel those of fentanyl and alfentanil. (Beers 
et al 2004). Also, no histamine release is documented aft er remifentanil administration. 
(Fukuda 2005). 50% reduction in isofl urane MAC may be achieved at remifentanil whole 
blood concentration of 1.37 ng/ml.
Opioids that are oft en compared to tramadol in analgesic potency are codeine and bu-
prenorphine. Both are so called weak opioids and have a plateau in dose-response curve. 
Buprenorphine is a semisynthetic derivative of thebaine and is a partial μ-opioid receptor 
agonist and κ-receptor antagonist with a long duration of action (Boothby 2007). Th e opioid 
antagonist eff ects observed with buprenorphine treatment are similar to those observed 
with naloxone. Th e pharmacokinetic and pharmacodynamic profi les of buprenorphine are 
not well characterized; however, the respiratory depressant eff ects of buprenorphine are 
similar to those of morphine when equipotent doses are used (Boothby 2007). Codeine 
is a weak μ-receptor agonist and is metabolized via CYP4502D6 by 10% into morphine. 
Codeine analgesia depends on this metabolism. (Lötsch 2005b).
5.7  Ketamine
Ketamine is a non-opioid drug, which acts as an antagonist of N-methyl-D-aspartate 
(NMDA) –receptors in the CNS. Ketamine also possesses some activity towards non-
NMDA glutamate receptors, opioid receptors, monoaminergic receptors and cholinergic 
receptors. However, the clinical signifi cance of these actions is not clear (Hirota et al 1996). 
Commercial Ketamine is available as a pure S (+)-enantiomer and as a 1:1 racemic mixture 
of S (+)-ketamine and R (-)-ketamine. S (+)-ketamine has been shown to be three times 
more potent than R (-)-ketamine. Ketamine has a relatively short distribution half-life of 24 
seconds and elimination half-life of t1/2α 5–17 minutes and t1/2β 137–180 minutes (Clements 
et al 1981, Reich et al 1989). Ketamine is metabolized by the liver, the most important 
pathway being N-demethylation by CYP450 to norketamine, an active metabolite with an 
anesthetic potency one third of that of ketamine (Reich et al 1989).
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Ketamine induces a dose-dependent depression of CNS that leads to a so-called dis-
sociative state, characterized by profound analgesia and amnesia but not necessarily loss 
of consciousness. Racemic ketamine produces anesthesia with doses of 1–2 mg/kg, but 
analgesia can be achieved with smaller doses, i.e. 0.25–0.5 mg/kg (Clements et al 1981, 
Kohrs et al 1998). In contrast to other anesthetic agents, the use of ketamine is favored 
by its minimal eff ects on respiration and its ability to stimulate hemodynamics. Ketamine 
is reported either to stimulate (Soliman et al 1975, Roytblat et al 1986, Morel et al 1986), 
depress or have no eff ect at all on respiration; however, all these eff ects are considered clini-
cally minimal (Corssen et al 1966, White 1982). Ketamine also acts as a bronchodilatator 
and it generally preserves airway patency, which both contribute to preserved respiratory 
function. Ketamine has negative inotropic actions on the myocardium, but it has a cen-
trally mediated ability of catecholamine release, which results in an increasing HR, blood 
pressure and CO (Traber et al 1968). Whole body and myocardial VO2 is increased aft er 
ketamine administration, most probably due to the increased sympathetic tone (Tweed et 
al 1972, Taittonen et al 1998). 
Th e use of ketamine as a sole agent is limited by its unpleasant psychotomimetic actions: 
hallucinations and vivid dreams. Th erefore, ketamine is oft en combined with other seda-
tives or analgesics in order to counteract both psychomotor and cardiovascular eff ects. 
Ketamine has been combined with benzodiazepines like midazolam (Taittonen et al 1998), 
anesthetics like propofol (Hui et al 1995), α2-agonists like clonidine and dexmedetomidine 
(Levänen et al 1995, Taittonen et al 1998) and opioids like morphine (Bourke et al 1987, 
Edwards et al 1993). 
5.8  Effect of pain on breathing and hemodynamics
Both injury-related and experimental pain can change breathing pattern and induce vari-
ous changes in ventilatory dynamics. In general, pain, including surgery, is reported to 
antagonize the respiratory depression induced by opioids. In experimental studies, pain 
stimulation can be achieved by diff erent methods. In the cold pressor pain test the upper 
arm is immersed in ice water for a certain period of time. In the dental stimulation pain test, 
an electrical current is conducted to a tooth with a predetermined current. In tourniquet 
pain testing, both upper and lower extremities can be used for keeping a tourniquet infl ated 
for a certain period of time (Hagenouw et al 1986). Th e upper arm tourniquet technique 
can be further extended by the subject squeezing a hand exerciser during the tourniquet 
infl ation (Smith et al 1966). In a study of Borgbjerg et al (1996) and Nishino et al (1999), 
the tourniquet infl ation increased VT, VE and the mouth occlusion pressure response to 
CO2. Th e tourniquet technique produced an increase in blood pressure, whereas the HR 
remained at the baseline level (Hagenouw et al 1986).
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5.9  Effect of oxygen on breathing
Oxygen is frequently administered in conjunction with opioids in order to prevent hypoxia 
due to ventilatory depression (Bailey et al 2000). However, the eff ect of supplemental oxygen 
on ventilatory function is not necessarily benefi cial. Th e use of hyperoxygenation during 
the induction of anesthesia produces more atelectasis than lower oxygen concentrations. 
Th is atelectasis formation is associated with low lung volumes, i.e. volumes close to residual 
volumes. Even the use of 30% supplemental oxygen is associated with increased atelectasis 
formation (Nunn et al 1978, Rothen et al 1995, Reber et al 1996) Th e formation of atelectasis 
correlates with the formation of shunt and arterial desaturation (Reber et al 1996).
Administration of oxygen to healthy volunteers during constant end-tidal CO2 stimulates 
ventilation by increasing VE in dose dependent fashion. Aft er 30 minutes of 75% O2, VE 
is more than doubled and even aft er 30% O2, VE is increased 20%. Th e increase in VE is 
mainly due to increase in VT; however, respiratory rate was also increased with higher 
oxygen concentrations. If normocapnia is not maintained, hyperventilation is attenuated 
by a decrease in PaCO2. Th e reason for this phenomenon is thought to be a result of  the 
Haldane eff ect, in which noroxygenated hemoglobin has a higher transport capacity for 
CO2 than does oxygenated hemoglobin because of the reduced carbamino carriage and 
the decreased buff ering capacity of oxygenated blood (Becker 1995, 1996).
5.10  Respiratory measurements
Th e eff ects of opioids on the regulation of breathing may be studied by analyzing the 
breathing pattern and gas exchange in undisturbed subjects at rest or by analyzing the 
response of ventilation to challenges, such as increased CO2 or decreased O2 tension (Mc-
Clain et al 1984).
5.10.1  Measurements of resting ventilation
5.10.1.1 Analysis of breathing pattern
Th e breathing movement can be regarded as a mechanical event in the respiratory control 
mechanism. Traditionally, breathing pattern has been analyzed solely as tidal volume (VT) 
and frequency (Fr), which are the determinants of minute volume (VE). Th e respiratory 
cycle can further be described by the duration of inspiration (TI), duration of expiration 
(TE) and total cycle duration (TTOT). VE  can be splitted into driving and timing components 
as follows:
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VE = Fr x VT = 1/TTOT x VT/TI x TI = VT/TI x TI/TTOT 
VT/TI is an index of the intensity of respiratory drive and TI/TTOT represents timing of the 
respiratory cycle. Th e relationship of VT/TI to airway occlusion pressure (P0.1), a classical 
index of respiratory drive, is well established (Milic-Emili 1982, Tobin et al 1983, McClain 
et al 1984).
5.10.1.2 Pneumotachometry
In the intubated patient, ventilation can be easily measured by attaching a spirometer or 
pneumotachograph to the patient’s endotracheal tube. With spirometer the change in 
spirometer volume is being recorded and with pneumotachometer the pressure diff erence 
across the pneumotachometer head is proportional to fl ow, which is then integrated to 
volume signal. (Jordan 1982). In non-intubated patients, these methods necessitate the 
use of tight-fi tting face masks or mouthpieces, which can produce spurious alterations 
in breathing pattern, causing VT to increase and respiratory frequency to decrease with 
unpredictable changes in VE and increases in VT/TI (Gilbert et al 1972, Jordan 1982, 
Weissman et al 1984, Han et al 1997). Th e use of a face-mask can also add dead space and 
resistance to breathing. However, the use of a spirometer enables the measurement of P0.1, 
a characteristic of respiratory drive (Jordan 1982, McClain et al 1984).
5.10.1.3 Airway occlusion pressure
P0.1 can be obtained by performing inspiratory occlusions without warning at irregular 
intervals and by measuring the change in airway pressure at 0.1 seconds aft er starting the 
occlusion. P0.1 is used as an index of respiratory center motor output and correlates well 
with the diaphragmatic electromyogram and increases linearly with CO2 tension (Jordan 
1982, McClain et al 1984).
5.10.1.4 Respiratory inductive plethysmography 
Respiratory inductive plethysmography (RIP) is a device developed for quantitative and 
noninvasive measurements of resting ventilation. RIP is based on the magnetometry 
principle established by Konno and Mead (1967). Th ey found that movements and volume 
changes of the respiratory system can be approximated to two degrees of freedom of mo-
tion. At any given moment the total change in the volume of the respiratory system will 
correspond to the sum of the volume changes in the thoracic and abdominal compart-
ments. Th e respiratory movements of the rib cage and abdominal compartments can be 
measured by external sensors, i.e., magnetometers as originally described by Konno et al 
1967 or inductive plethysmograph (Milledge et al 1977), and calibrated to yield quantitative 
data (Sackner et al 1989). Th e RIP represents a modern application of the Konno-Mead 
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principle. It provides a good accuracy of volume measurement over a wide range of body 
positions (Jordan 1982, Watson et al 1988, Valta et al 1992). 
5.10.2  Ventilatory challenges
Respiratory center output is typically measured with ventilatory challenges. Ventilation can 
be challenged either by hypercapnia or hypoxia. Th e response of ventilation to an increase 
in CO2 is considered a particularly sensitive test of respiratory depression (McClain et al 
1984). Increases in PaCO2 stimulate the peripheral arterial chemoreceptors directly and 
the central chemoreceptors in the brain indirectly through concomitant changes in brain 
extracellular pH. Th e respiratory centers of pons and medulla respond to the information 
from the chemoreceptors and increase ventilation in order to keep PaCO2 constant (Jordan 
1982). In the hypercapnic ventilatory challenge, the fraction of inhaled CO2 is increased 
either stepwise as in the steady-state method or more commonly linearly with the rebreath-
ing method (Read et al 1967). VE is then measured together with PaCO2 and plotted on 
a linear curve. Th ere is a wide variability in the slope of the ventilatory response to CO2 
between individuals. Th e day-to-day variability within individuals is also large. Ventilatory 
challenges can also induce changes in hemodynamics. Th e steady-state method produces 
clear increases in blood pressure, heart rate and decrease in total peripheral resistance 
(Cullen et al 1974).
Hypoxia stimulates ventilation primarily through its action on carotid body chemorecep-
tors. Th e ventilatory response to change in oxygen tension is very rapid and might even 
be more sensitive than the response to increased CO2 (McClain et al 1984). In the hypoxic 
ventilatory challenge (hypoxic roll-off ) the inspired oxygen fraction is continuously or 
stepwise decreased and sustained for 20 minutes and VE measured at certain PaO2 levels. 
5.10.3  Measurements of gas exchange
5.10.3.1 Indirect calorimetry
Originally, the rate of whole-body VO2 is based on an application of Fick’s equation: VO2 
= CO x AVDO2, where AVDO2 is the diff erence in arterial and mixed venous blood O2 
content. However, the use of the Fick’s equation requires the use of pulmonary artery 
catheterization and it gives only a single measurement of VO2. Furthermore, it does not 
measure whole body VO2, because it excludes lung parenchymal VO2.
Indirect calorimeters are devices designed to measure VO2 and VCO2 in order to calculate 
metabolic rate. Th ey are divided into open-circuit and closed-circuit categories. Th e open-
circuit system is analogous to the so-called Douglas bag method, where the determinants of 
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VO2 and VCO2 are the diff erences between inspired and expired O2 and CO2 concentrations, 
and expired VE (Meriläinen 1987, 2000).
Using a specially designed canopy, these measurements can be performed in non-intubated 
spontaneously breathing patients. As no mouthpiece is needed, indirect calorimetry does 
not cause changes in breathing pattern or lung volumes. Th e sensitivity and accuracy of 
O2 and CO2 sensors make rapid and precise analysis of VO2 and VCO2 possible. Th is has 
expanded their use from metabolic rate studies to ventilatory measurements.
5.10.3.2 Blood gas analysis
Measurements of arterial blood-gas tensions are the mainstay of the clinical assessment 
of ventilation, although the information obtained has its limitations (McClain et al 1984). 
Arterial blood sampling and subsequent blood-gas analysis enable PaO2, PaCO2 to be 
measured directly. Adequacy of ventilation may be assessed from measurements of arte-
rial PCO2, an increase in PaCO2 implying that VA has diminished in relation to VCO2. 
Measurements of PaO2 are generally considered less useful in measurements of ventilatory 
function, since it is dependent on the relative distribution of pulmonary ventilation and 
perfusion (Jordan 1982).
5.10.3.3 Alveolar ventilation
VA is referred as the portion of VE that respires, i.e. removes CO2 from the blood and 
transfers O2 through the lungs to the blood. The portion of VE that does not respire is 
designated as dead space ventilation (VD). The rate of carbon dioxide production (VCO2), 
obtained from indirect calorimetry, and the alveolar partial pressure of carbon dioxide 
(PACO2) thus determine the need for alveolar ventilation (Kiiski et al 1991, Tulla et al 
1995.) PaCO2 is a function of PACO2. The correlation between metabolism and breathing 
can be expressed mathematically by the Bohr equation: VE = k x VCO2/PaCO2 x (1-VD/VT), 
with k=0.115  in spontaneously breathing patients and k=0.863  in intubated patients. VA 
is further determined by VA = VE x (1–VD/VT) (Kiiski et al 1994).
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6 AIMS OF THE STUDY
Th e aim of the study was to clarify the eff ects of diff erent opioids and ketamine on respira-
tion and hemodynamics in healthy volunteers and trauma patients. Respiratory depression, 
evaluated as changes in breathing pattern, gas exchange and blood gas values, was the main 
parameter in this study.
Th e specifi c aims of this study were
- To evaluate the native respiratory eff ects of i.v. morphine (III), oxycodone (III, V), 
pethidine (II), tramadol (II), fentanyl (I and IV) and alfentanil (IV).
- To calculate the potency ratio for respiratory depression of fentanyl and alfentanil at 
steady-state plasma concentrations (IV).
- To evaluate whether ketamine could attenuate fentanyl-induced respiratory depression 
(I).
- To investigate the immediate cardiovascular responses to i.v. morphine and oxycodone 
under experimental pain (III) and the cardiovascular responses to i.v. fentanyl- (IV), 
alfentanil- (IV), pethidine- (II) and tramadol- (II) infusions.
- To investigate the eff ects of opioids on plasma catecholamine and histamine concen-
trations during experimental pain (II,III)
- To evaluate the eff ect of supplemental oxygen on respiration and atelectasis formation 
on trauma patients treated with oxycodone (V)
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7 SUBJECTS AND METHODS
7.1  Volunteers and patients
Studies I–IV were carried out at Turku University. Th ese studies each involved 8 healthy 
male volunteers, age 22–35 years. All volunteers were interviewed and clinically examined 
before participation. Before study IV a drug-screening test was also performed. No alcohol 
or drug abuse, allergy, permanent medication, smoking >10 cigarettes/day were allowed for 
any of the subjects. Study V was carried out in the emergency department of the trauma 
center of Helsinki University Hospital, Töölö Hospital during November 1997–May 1998. 
Th is study involved 13 patients, 8 male and 5 female with mean age 15–58 years. Patients 
with lower or upper extremity injury without any injury to head, thorax or abdomen were 
included in the study. Th e participants were recruited right aft er arrival to the emergency 
room.
7.2  Ethical aspects
Th e studies were conducted in accordance with the guidelines of the declaration of the 
World Medical Assembly of Helsinki. Th e study protocols of studies I–IV were approved by 
the Joint Commission on Ethics of the Turku University and the Turku University Hospital, 
and study IV was also approved by the Finnish National Agency for Medicines. Th e study 
protocol of study V was approved by the Ethics Committee of Töölö Hospital in Helsinki 
University Hospital. Before participating, all volunteers and patients were informed about 
the purpose and nature of the study. A written informed consent was obtained form each 
volunteer and patient.  
7.3  Study design
Th e summary of the study designs is presented in Table 3. Also, the general setting of 
studies I–IV is depicted in Figure 1.
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Table 3. Summary of the study designs
Study 
number
Number of 
volunteers/
patients
Design Drugs, doses, timing Key parameters
I 8 volunteers Double-blind, 
randomized, 
cross-over, 
placebo-
controlled
Fentanyl 2μg/kg+ Ketamine 
0.25 mg/kg or
Fentanyl 2μg/kg+placebo
VE, VA, VO2, SpO2, 
MAP, HR
II 8 volunteers Double-blind, 
randomized, 
cross-over, 
controlled
Tramadol 150 mg bolus + 250 
mg 3 h infusion 
or
Pethidine 112.5 mg bolus + 
187.5 mg 3 h infusion
SpO2, VT, RR, VT/TI
Plasma 
catecholamines
III 8 volunteers Double-blind, 
randomized, 
cross-over, 
placebo-
controlled
Morphine 0.07 mg/kg 
or 
Morphine 0.14 mg/kg
or
Oxycodone 0.14 mg/kg or 
placebo
MAP, HR, VO2, 
Plasma histamine 
and catecholamines, 
VA
IV 8 volunteers Double-blind, 
randomized, 
cross-over, 
controlled
Alfentanil as 5,8,12.5,20,31.5,
50,80,125,200,315,500 ng/ml 
concentrations 
and 
Fentanyl as 0.1,0.16,0.25,0.4, 
0.63,1.0,1.6,2.5,4.0,6.3, 10 ng/
ml concentrations
Pharmacodynamic 
modeling, VE, RR, 
PaCO2, VA
V 13 trauma 
patients
Randomized, 
controlled
Oxycodone 0.08 mg/kg                 
(+ additional 0.04 mg/ml if 
requested) for all patients
40% oxygen or room air
Atelectasis 
formation, PaO2, 
SpO2
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Figure 1. Th e general setting of studies I–IV.
Study I. Th e eff ect of low-dose ketamine 0.25 mg/kg on the respiratory depression induced 
by fentanyl 2 μg/kg was studied in eight healthy volunteers. Th e eff ects of fentanyl+ketamine 
and fentanyl+placebo on VE, VA, VO2, PaO2, SpO2, MAP and HR were measured during a 
60-minute follow-up period. Th e study was performed in randomized, placebo-controlled, 
double-blind and cross-over fashion.
Study II. Tramadol 150 mg i.v. bolus followed by 250 mg as 3 hour steady i.v. infusion 
were compared to those of pethidine 112.5 mg IV bolus followed by 187.5 mg as 3 hour 
steady i.v. infusion during experimental pain stimulus. Breathing pattern, PaCO2, SpO2, 
MAP, HR and plasma catecholamines were measured in eight healthy volunteers, studied 
in randomized, cross-over and double-blind fashion. All measurements were performed 
until 60 minutes aft er cessation of the infusion.
Study III. Th e initial eff ects of single i.v. dose of morphine 0.07 mg/kg, 0.14 mg/kg and 
oxycodone 0.14 mg/kg during fi rst 30 minutes on MAP, HR, VO2, VA, PaO2 and plasma 
catecholamines and histamine were studied in eight healthy volunteers in randomized, 
cross-over, double-blind and placebo-controlled fashion. Experimental pain stimulus was 
used during the study. 
Study IV. Th e potency ratio for respiratory depression of alfentanil and fentanyl was stud-
ied during logarithmically escalating plasma pseudo-steady-state alfentanil and fentanyl 
concentrations. Th e drugs were delivered with a computer controlled infusion pump and 
the infusions were terminated when respiratory rate decreased to 2/min or SpO2 decreased 
below 85%. During the infusions, VE, VA, breathing pattern, VO2, VCO2, PaO2, PCO2, MAP, 
HR as well as plasma alfentanil and fentanyl concentrations were measured. Pharmaco-
dynamic modeling was performed in order to calculate EC50 values for VE and respiratory 
rate as well as a linear model in the increase in PaCO2. Th e study was performed in eight 
healthy volunteers in randomized, double-blind, cross-over fashion.
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Study V. Th e eff ect of supplemental oxygen on respiration of opioid-treated trauma patients 
was studied in randomized and controlled fashion in 13 patients. Patients with upper or 
lower extremity trauma were given i.v. oxycodone 0.08 mg/kg and randomized to either 
breathe 40% oxygen via facemask or room air. Additional oxycodone 0.04 mg/kg i.v. was 
given, if so requested by the patient. SpO2, PaO2, PaCO2, MAP and HR monitored starting 
5 minutes before and continued up to 30 minutes aft er fi rst oxycodone administration. 
Aft er 30 to 60 minutes a computer tomography of the chest was performed in order to 
evaluate atelectasis formation.
7.4  General considerations
Th e general study setting used in studies I–IV is presented in Figure 1. During studies I–IV 
no food, caff einated drinks or chocolate were allowed up until 12 hours before the study 
session. No alcohol was allowed on the preceding day of the studies. To exclude diurnal 
variation, both sessions for each subject were performed at the same time of the day. Dur-
ing the experiments the subjects were breathing room air and were resting supine in bed 
in a normally lighted room with ambient room temperature. Th e double-blind nature of 
the studies was ensured by having an independent person not participating in the actual 
study prepare the study drugs into ready-to-inject form. Physiologic saline was used as 
placebo in studies I and III. No glucose was infused during the study periods of studies 
I–IV. Th e washout period between study session in studies I–IV varied from 5 days to 3 
weeks. During study V the patients lay in hospital beds and were instructed to lie quietly 
unless they had any complaints. Ringer’s acetate was infused during study V for all patients, 
approximately 50–100 ml/h. 
7.5  Study drugs
Th e following drugs were used during the study: morphine (Morfi n©, Leiras, Turku, Fin-
land), oxycodone (Oxanest©, Leiras, Turku, Finland), pethidine (Petidin©, Leiras, Turku, 
Finland), tramadol (Tramal©, Orion-Farmos, Espoo, Finland), fentanyl (Fentanyl©, Orion-
Farmos, Espoo, Finland), alfentanil (Rapifen©, Orion-Farmos, Espoo, Finland), ketamine 
(Ketalar©, Parke-Davis, Detroit, USA).
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7.6  Measurements
7.6.1 Respiratory monitoring
7.6.1.1 Respiratory inductive plethysmography
Th e respiratory inductive plethysmograph (RIP, Respitrace TM, NIMS, Miami Beach, FL, 
USA) was used in studies I, II, IV for measurement of breathing pattern, in addition to 
this in studies I and IV for measurement of minute ventilation. In studies III and V RIP 
was used for measurement of respiratory rate and as an apnea monitor. Changes in rib 
cage (RC) and abdominal circumferences (AB) were simultaneously measured using two 
diff erential linear transformers connected to tight fi tting belts around the chest at nipple 
level and around the abdomen at umbilical level. As the respiratory movements change the 
cross-sectional areas of the rib cage and the abdominal compartments, the self-inductance 
of insulated wire coils worn around the rib cage and the abdomen changes in proportion to 
the change of the cross-sectional area during tidal breathing. Th e respiratory movements 
produce variation in the self-inductance of the transducer. Th e signal obtained from this 
is demodulated to produce analog waveforms of RC and AB excursions and the sum 
signal. Th e sum signal can be calibrated against a volume reference to provide volumetric 
measurements (Sackner et al 1989). 
In the beginning of studies I and IV, the RIP was calibrated using the semi-quantitative 
single-position calibration method designed by Sackner et al (1989). Baseline breathing 
was fi rst collected for fi ve minutes and thereaft er calibrated against a calibrated heated 
pneumotachometer (PT) (Hans Rudolph Inc, Kansas City, MO, USA), connected to a 
diff erential pressure transducer (Validyne MP 45, ±2.0 cmH2O; Validyne Co, Northridge, 
CA, USA). Flow, volume and analog RC+AB signals were amplifi ed and recorded using 
a physiologic recording system (Direc, Raytech Instruments, Vancouver, Canada). Th e 
calibration of RIP was completed by comparing the VT determined by the RIP against those 
determined by the PT. At least fi ve breaths were sampled for calibration. Th e calibrated 
sum signal was analyzed with a soft ware program (Respievents, NIMS) provided with the 
RIP. Th e calibration was validated and accepted only if the measured error of the sample 
of breaths was within the range of ± 5%. For each measuring point breathing pattern or 
respiratory rate was measured for 2 minutes. VE was calculated from VT and respiratory 
rate. VT/TI was calculated dividing VT with TI. Also, the proportion of total ventilation that 
can be attributed to expansion of rib cage (RC%) was measured.
In the beginning of studies II, III and V no volumetric calibration was performed. Otherwise 
the design was similar to studies I and IV. 
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7.6.1.2  Arterial blood gas analysis
Arterial blood from a cannula inserted in the radial artery was drawn for analysis of PO2 
and PCO2 in all of the studies. Th e blood samples were chilled on ice an analyzed within 
20 minutes.
7.6.1.3  Arterial hemoglobin oxygen saturation
SpO2 was recorded in all studies using a pulse oximeter (Cardiocap, Datex-Ohmeda, 
Helsinki, Finland) with a fi nger probe.
7.6.1.4 Alveolar ventilation
VA was calculated according to formula VA = 0.115 x VCO2 (ml/min)/PaCO2 (kPa) (Kiiski 
et al 1994, Tulla et al 1995).
7.6.2  Hemodynamic measurements
In all studies MAP and HR were directly recorded from the radial artery (Cardiocap, 
Datex-Ohmeda, Helsinki, Finland). In studies II, IV and V continuous monitoring of ECG 
was also performed (Cardiocap, Datex-Ohmeda, Helsinki, Finland). Collect-program 
(Datex-Ohmeda, Helsinki, Finland) was used for the collection of hemodynamic and 
metabolic data in all the studies.
7.6.3  Measurements of gas exchange
Th e gas exchange measurements in studies I, III and IV were performed using an open-
system indirect calorimeter Deltatrac® (Takala et al 1989). 
For the measurement of spontaneously breathing patients, the subjects head is placed un-
der a plastic canopy connected to the analyzer (Meriläinen 1987). Th e diff erence between 
FiO2 (measured at the entry valve of the canopy) and FeO2 is measured with fast-response 
paramagnetic diff erential O2 sensor (OM-101, Datex/Instrumentarium, Helsinki, Finland). 
Th e FeCO2 is measured with an infrared CO2 sensor. 
VCO2 is calculated as the product of the constant fl ow and the fraction of CO2 in the 
diluted expiratory fl ow: VCO2 = Q x 1/FeCO2, where Q is the constant fl ow. Th e VO2 is 
calculated using the Haldane transformation: VO2 = VCO2/RQ, where VCO2 = Q x 1/FeCO2 
and RQ = 1-FiO2/((FiO2-1/FeO2)/FeCO2) – FiO2). FeO2 and FeCO2 are the fraction of O2 
and CO2 in the mixed expiratory gas fl owing through the monitor (Meriläinen 1987). Th e 
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Deltatrac monitor was calibrated with a gas mixture of 5.0±0.03% CO2 and 95±0.03% O2 
(Calibration Gas, Datex).
7.6.4  Biochemical determinations
Arterial blood samples were drawn from the radial artery for measurements of plasma 
epinephrine and norepinephrine (II,III), histamine (III) and alfentanil and fentanyl (IV) 
concentrations. Th e blood samples were collected in pre-cooled EDTA-tubes, chilled on 
ice, and promptly centrifuged at 4°C. Plasma was stored at -70°C until analysis. 
Plasma concentrations of catecholamines were determined using high-performance liquid 
chromatography (HPLC) with electrochemical detection (Scheinin et al 1991). Th e intra-as-
say coeffi  cients of variation were <2% for norepinephrine and 10% for epinephrine. Plasma 
concentrations of prolactin were determined using a commercially available radioimmu-
noassay (RIA, Orion Diagnostica, Espoo, Finland). Plasma concentrations of histamine 
were determined with high-performance liquid chromatography by using a cation exchange 
column with postcolumn derivatization and fl uorescence detection (Yamatodani 1985, 
1991). Plasma levels of alfentanil and fentanyl were determined using radioimmunoassay 
methods (Michiels et al 1983, Woestenborgh et al 1987).
7.6.5  Computer controlled infusions
In study IV alfentanil and fentanyl were delivered with a computer driven (STANPUMP) 
infusion pump (Harward 22 Basic Syringe Pump, Harward Apparatus, South Natick, MA, 
USA) based on a pharmacokinetic model. (Scott et al 1987, Shafer et al 1991). Ascending 
logarithmic escalations of pseudo steady-state plasma drug concentrations were accom-
plished at 10 minutes intervals.
7.6.6  Pharmacodynamic modeling
In study IV pharmacodynamic modeling was performed separately for each subject using 
the nonlinear regression program PCNONLIN (Version 4.2, Scientifi c Consulting Inc., Apex, 
NC, USA) without weighting. Th e concentrations producing 50% of the maximal decrease 
in VE and respiratory rate (i.e. apparent EC50 values) were estimated by fi tting the fractional 
Emax and sigmoidal Emax models to the data according to equations 1 and 2, respectively,
E  =  E0 × [1-C/(EC50 + C)]  (1)
E  =  E0 × [1-Cγ/(EC50γ + Cγ)]  (2)
39SUBJECTS AND METHODS
where E is eff ect, E0 is baseline eff ect (maximal drug eff ect, Emax is equal to E0), C is drug 
concentration, EC50 is concentration at 50% of Emax and γ is sigmoidicity (Hill) factor. 
(Bouillon et al 1999). Th e goodness of the fi ts was determined by Akaike’s information 
criterion and by assessment of scatter of the observed data points in relation to the fi tted 
function. In addition, the increase in PaCO2 was fi tted to a linear model, i.e.
E  =  E0+ k × C  (3)
where k is the slope of the line relating eff ect to concentration.
7.6.7 Pain assessment
Pain stimulus was used in studies II and III. Experimental pain was induced using a 7-cm 
wide upper arm tourniquet infl ated to 300 mmHg for 5 (II) or 10 (III) minutes as described 
by Hagenouw et al (1986). In study II pain stimulus was used at baseline, aft er the bolus 
dose of study drugs and at the end of drug infusion. In study III pain stimulus was started 
prior to drug injection and lasted up to 4 minutes aft er drug injection.
7.6.8 Subjective assessments
VAS-scales with subject marking on a 10-cm long ungraded horizontal line with opposite 
extremes at each end were used to obtain subjective estimates on the experience of pain 
(II), nausea (II,III), euphoria and dysphoria (I,III), dizziness, dryness of mouth and seda-
tion (I) (Maxwell 1987).
7.6.9 Radiological assessment
In study V, 12 of 13 patients recruited in the study went through a CT scan of chest for 
evaluation of atelectasis. No CT-scan was performed on one patient because of technical 
problems. For the CT scan (GE HiSpeed) the subjects were supine with their arms above 
the head. A spiral CT of the lungs was performed at the end of inspiration, the slice thick-
ness being 1 mm with 10 mm intervals (erratum in the Study V). No contrast medium was 
used. All CT images were evaluated and atelectasis or other signs of hypoventilation were 
recorded as “yes” or “no”. Two CT scans from each patient were chosen for further analysis. 
Th e chosen scans were 6 cm (upper) and 2cm (lower) above the diaphragm. A region of 
interest (ROI) was drawn in both lungs separately. Th is region excluded the outermost part 
of the lung to avoid partial volume eff ect. Also, the great vessels were excluded medially. 
A histogram of the distribution of pixel density was made in these ROI areas and lung 
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density was defi ned in terms of Hounsfi eld units (Lundquist et al 1995). A value above 
500 Hounsfi eld units was considered a poorly areated lung. Th e calculations were carried 
out both on the right and left  lung separately. 
7.6.10 Statistics
In studies I,II and III statistical analysis was performed using Statview SE Graf soft ware 
for Macintosh (Abascus Concepts, Berkely, CA, USA). Students unpaired t-test was used 
for statistical analysis for comparisons between treatments (I,II). Repeated measurements 
were taken to compare drug eff ect between treatments (III) and time-diff erence within 
treatment groups by using two-way analysis of variance (ANOVA) (I,II,III). If statistical 
signifi cance was reached, multiple comparisons were made with Fishers protected least 
signifi cance (PLSD) test (I,II,III).
In study IV the diff erent pharmacodynamic responses were analyzed using analysis of 
variance for crossover design with repeated measures within periods. In this analysis, 
a signifi cant step eff ect was indicative for concentration dependent eff ects, and the two 
factor interaction sequence*period or the three factor interaction sequence*period*step 
indicative for diff erences between the two study drugs. To assess the sensitivity of the vari-
ous respiratory variables to detect drug-induced respiratory depression, the analysis was 
continued in case of a signifi cant concentration eff ect by calculating paired contrasts vs. 
baseline and by correcting corresponding p-values for multiple comparisons (Bonferroni 
correction). In addition, 95% confi dence intervals were calculated for the estimated EC50 
values and potency ratios. Statistical computing was performed using the SAS system for 
Windows (Release 6.12, 1996, SAS Institute Inc., Cary, NC, USA).
In study V comparison between the study groups were performed using unpaired Student 
t-test. To test the signifi cant time-eff ect within the study groups, a repeated measure-
ment-linear model was used. Statistical computing was performed using the SAS system 
for Windows.
A p-value less than 0.05 was considered as statistically signifi cant. Data is given as 
mean±SD. 
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8     RESULTS
8.1 Respiratory effects
8.1.1 Effects on ventilation (VE and VA)
A single bolus of fentanyl 2 μg/kg decreased VE and VA signifi cantly (p<0.05) (I). Adding 
ketamine 0.25 mg/kg to fentanyl attenuated this decrease signifi cantly (p<0.05). A single 
bolus of morphine 0.07 mg/kg decreased VA signifi cantly up to 15 minutes aft er the injection 
(p<0.05), whereas a higher dose of morphine 0.14 mg/kg decreased VA up to 20 minutes 
aft er the injection (p<0.05) (III). Th e initial decrease in VA aft er oxycodone 0.14 mg/kg 
was signifi cantly deeper than aft er morphine, from 4.9 l/min to 2.9 l/min, during the pain 
stimulus (p<0.05). During escalating plasma pseudo-steady state alfentanil and fentanyl 
concentrations VE decreased similarly during both infusions (IV). A signifi cant decrease 
(p<0.05) was noted at targeted plasma concentration level of 31.5 ng/ml for alfentanil 
and 0.63 ng/ml for fentanyl. Th e calculated apparent EC50 of VE for alfentanil was 234±57 
ng/ml and for fentanyl 6.1±1.4 ng/ml, with a potency ratio of 1:39. A signifi cant decrease 
in VA was detected at alfentanil concentration of 12.5 ng/ml and at fentanyl concentration 
of 0.25 ng/ml (p<0.05). Th e total decreases in VA and VE during alfentanil and fentanyl 
treatments were highly signifi cant (p<0.001). Th e measured and predicted alfentanil and 
fentanyl concentrations are presented in Figure 2.
Figure 2. Targeted (solid lines) and mean (SD) measured (fi lled squares) fentanyl and 
alfentanil plasma concentrations in study IV
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8.1.2 Effects on breathing pattern
Respiratory rate decreased aft er opioid administration. Fentanyl 2 μg/kg with or without 
ketamine decreased respiratory rate signifi cantly (p<0.05) (I). Tramadol 150 mg IV bolus 
increased respiratory rate transiently (p<0.05), but infusion of 250 mg tramadol in 3 hours 
did not aff ect respiratory rate (II). No decrease in respiratory rate was detected at 5 minutes 
aft er a i.v. bolus of 112.5 mg pethidine, however during the 3 hours infusion of 187.5 mg 
pethidine respiratory rate decreased slightly but signifi cantly (p<0.05). Aft er morphine 0.07 
mg/kg, morphine 0.14 mg/kg and oxycodone 0.14 mg/kg respiratory rate was signifi cantly 
decreased (p<0.05), with a greatest decrease aft er oxycodone administration (p<0.05) (III). 
When oxycodone 0.14 mg/kg was given to trauma patients, the decrease in respiratory 
rate was minimal and did not reach signifi cance (V). Escalating alfentanil and fentanyl 
concentrations caused a signifi cant decrease in respiratory rate at a concentration level of 
20 ng/ml for alfentanil and 0.4 ng/ml for fentanyl onwards (p<0.05) (IV). Th e total decrease 
in respiratory rate during these infusions were highly signifi cant (p<0.001). Th e calculated 
apparent EC50 for respiratory rate was 195±101 for alfentanil and 3.5±1.4 for fentanyl.
VT was increased aft er opioid administration. Fentanyl 2 μg/kg with and without ketamine 
0.25 mg/kg increased VT signifi cantly (p<0.05) (I). Tramadol given as bolus increased VT, 
but during tramadol infusion VT was signifi cantly decreased (p<0.05). Bolus administration 
of pethidine decreased VT, but during pethidine infusion, VT was signifi cantly increased 
(p<0.05) (II). VT was not signifi cantly aff ected in trauma patients treated with oxycodone 
0.14 mg/kg (V). During fentanyl infusion an increase in VT was noted at plasma concen-
tration of 2.5 ng/ml and with alfentanil at plasma concentration of 125 ng/ml onwards 
(p<0.05). Th e total increase in VT during these infusions was highly signifi cant (p<0.001) 
(IV). All opioids given in studies II,IV aff ected breathing pattern signifi cantly as described 
in Table 4.
Table 4. Eff ects of opioid on breathing pattern
Drug VT/TI TI/TTOT RC%
Tramadol bolus
                inf
0
0
0
decreased
ND
ND
Pethidine bolus
                inf
0
increased
0
decreased
ND
ND
Alfentanil inf increased ND increased
Fentanyl inf increased ND increased
ND = not defi ned  VT/TI  = mean inspiratory fl ow       
TI/TTOT = inspiratory duty cycle  RC% = the proportion of ventilation that can be attributed to rib cage 
expansion
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8.1.3 Effects on arterial blood gases
Fentanyl 2 μg/kg caused a clear decrease in PaO2 (p<0.05), the decrease being similar with 
and without ketamine 0.25 mg/kg (I). Morphine 0.07 mg/kg as well as 0.14 mg/kg decreased 
PaO2 only slightly, although signifi cantly (p<0.05), whereas oxycodone 0.14 mg/kg caused 
a more profound decrease in PaO2, the lowest value being 9.7 kPa 4 minutes aft er drug 
injection (III). When oxycodone 0.14 mg/kg was given to trauma patients, PaO2 remained 
within normal values in patients breathing room air. In patients breathing 40% oxygen PaO2 
was increased well above baseline level (V). PaO2 was decreased signifi cantly from baseline 
values at alfentanil plasma concentration of 50 ng/ml and fentanyl plasma concentration 
of 1 ng/ml (IV). Fentanyl 2 μg/kg with or without ketamine 0.25 mg/kg increased PaCO2 
signifi cantly, with a peak eff ect at 15 minutes post injection (I). 
Tramadol 250 mg given in 3-hour infusion increased PaCO2 slightly, but signifi cantly 
(p<0.05) (II). Th e increase of PaCO2 during pethidine 187.5 mg infusion was greater 
compared to tramadol (p<0.05). Both morphine 0.07 mg/kg and 0.14 mg/kg increased 
PaCO2 signifi cantly, PaCO2 being elevated up to 30 minutes aft er the injection (p<0.05) (III). 
Th e increase in PaCO2 aft er oxycodone 0.14 mg/kg occurred earlier than aft er morphine 
(p<0.05) and was more profound (p<0.05), however the values started to decrease already 
at 20 minutes. In trauma patients treated with 0.14 mg/kg oxycodone, PaCO2 remained 
within normal limits (V). A signifi cant increase in PaCO2 was detected at alfentanil plasma 
concentration of 20 ng/ml and fentanyl plasma concentration of 0.4 ng/ml. Th e EC50 con-
centration to induce a 50% increase from baseline PaCO2 was 263±54 ng/nl for alfentanil 
and 6.2±1.5 for fentanyl.
8.1.4 Effects on arterial hemoglobin oxygen saturation
After fentanyl 2 μg/kg bolus SpO2 decreased from 97% to 90% with placebo and to 91% 
when ketamine 0.25 mg/kg was added (p<0.05) (I). Tramadol caused a oxygen saturation 
decrease from 98% to 96% during the 250 mg infusion (p<0.05), whereas pethidine 112.5 
mg bolus decreased oxygen saturation from 97% to 94% and during 187.5 mg pethidine 
infusion the lowest value was 95% (p<0.05) (II). The lowest values in oxygen saturation 
after morphine 0.07 mg/kg and 0.14 mg/kg were 97% and 96%, respectively (III). Oxy-
codone 0.14 mg decreased SpO2 more clearly. The lowest value 94% was reached at 4 
and 10 minutes post injection (p<0.05 from baseline). When oxycodone 0.14 mg/kg was 
given to trauma patients breathing room air, SpO2 decreased to 96% (V).  A signifi cant 
decrease from baseline in SpO2 was achieved at alfentanil plasma concentration 50 ng/ml 
and fentanyl plasma concentration of 1 ng/ml (p<0.05) (IV). The total decrease in SpO2 
during alfentanil and fentanyl infusion was highly signifi cant (p<0.001). 
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8.2. Effects on gas exchange
Fentanyl 2 μg/kg alone decreased both VO2 and VCO2 signifi cantly (p<0.05 from baseline). 
When ketamine 0.25 mg/kg was added to fentanyl, the eff ect on gas exchange was oppo-
site: VO2 increased signifi cantly (p<0.05 from baseline), whereas VCO2 was not aff ected 
at all (I). Aft er morphine 0.14 mg/kg VO2 increased signifi cantly (p<0.05), peaking at the 
termination of drug injection (III). Th e increase in VO2 aft er morphine 0.07 mg/kg did 
not reach signifi cance. Th e decrease in VO2 aft er oxycodone 0.14 mg/kg was slight and 
insignifi cant. VO2 was decreased during alfentanil and fentanyl infusions, being signifi cantly 
lower compared to baseline at plasma concentrations of alfentanil 20 ng/ml and fentanyl 
0.4 ng/ml (p<0.05) (IV). Th e decrease in VCO2 was noted at plasma concentrations of 8.0 
ng/ml for alfentanil and 0.16 ng/ml for fentanyl. Th e total decrease in both VO2 and VCO2 
was highly signifi cant during both infusions (p<0.001).
8.3 Hemodynamic effects 
A bolus of fentanyl 2 μg/kg decreased HR signifi cantly but did not aff ect MAP. Add-
ing ketamine 0.25 mg/kg to fentanyl caused a signifi cant increase in both HR and MAP 
(p<0.05) (I). Tramadol did not aff ect hemodynamics, whereas pethidine 187.5 mg infu-
sion slightly decreased HR from 67±12 bpm to 60±7 bpm (p<0.05). No eff ect was seen in 
MAP during pethidine administration (II). Both morphine 0.07 mg/kg and 0.14 mg/kg 
caused a signifi cant but transient increase in MAP and HR (p<0.05 from baseline), peak-
ing at termination of the bolus injection (III). Oxycodone 0.14 mg/ml decreased MAP at 
30 minutes aft er drug injection (p<0.05 from baseline), whereas HR was not aff ected by 
oxycodone. Oxycodone 0.14 mg/kg given to trauma patients did not signifi cantly aff ect 
MAP or HR (V). Neither alfentanil nor fentanyl infusion caused any changes in HR (IV) 
even at high plasma concentrations, and their eff ects on MAP were also minor. 
8.4. Effects on plasma catecholamines
Tramadol did not have any eff ect on plasma norepinephrine concentrations. A bolus of 
pethidine 112.5 mg increased plasma norepinephrine concentration signifi cantly, this 
increase persisted till the end of the 187.5 mg infusion. Both morphine 0.07 mg/kg and 
oxycodone  0.14 mg/kg increased plasma norepinephrine slightly but signifi cantly at 4 
minutes post drug injection.
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Plasma epinephrine concentrations were increased aft er tramadol 150 mg bolus and 250 
mg infusion (II), pethidine 112.5 mg bolus and 187.5 mg infusion (II) and morphine 
0.14 mg/kg bolus (III). Other treatments did not signifi cantly aff ect plasma epinephrine 
concentrations. 
8.5 Effects on plasma histamine
Aft er bolus of morphine 0.14 mg/kg, plasma histamine concentrations were increased 
slightly, but statistically signifi cantly (p<0.05) Th e smaller dose of morphine and oxycodone 
did not aff ect the plasma histamine concentrations (III).
8.6 Effects on atelectasis formation
In study V, no clinically signifi cant atelectasis formation was noted in any of the patients. In 
3/7 patients breathing 40% oxygen and 4/6 patients breathing room air there was evidence 
of minimal, clinically insignifi cant dorsal dependent atelectasis. No eff ect of supplemental 
oxygen was noted in the Hounsfi eld units, which ranged from –840±40 to –800±20, indica-
tive of well areated lung parenchyma. 
8.7 Adverse effects
A bolus of fentanyl 2 μg/kg with or without ketamine 0.25 mg/kg did not cause any euphoria, 
dysphoria, dizziness, and dryness of mouth or sedation (I). Tramadol treatment caused 
signifi cantly more nausea compared to pethidine (p<0.05) (II). Morphine 0.14 mg/kg 
and oxycodone 0.14 mg/kg caused signifi cantly more euphoria compared to morphine 
0.07 mg/kg and placebo (p<0.05) (III). One volunteer fainted 2 hours aft er morphine 0.14 
mg/kg administration and one volunteer vomited 60 minutes aft er oxycodone 0.14 mg/kg 
administration. However, no diff erence was found in the VAS scores of dysphoria and 
nausea between treatments. Both morphine doses, i.e. 0.07 mg/kg and 0.14 mg/kg caused 
redness and itching at the injection site. Th is was not seen aft er oxycodone and placebo 
injections. During study IV, one alfentanil infusion had to be terminated prematurely 
because of nausea and vomiting. In addition, one volunteer vomited aft er fentanyl infusion 
and two aft er alfentanil infusions. Four subjects reported itching and three subjects reported 
dryness of mouth aft er fentanyl and two aft er alfentanil infusions. One subject reported 
hallucinations during both infusions. During study V, one patient had a transient loss of 
P-wave in the electrocardiogram and one patient had a transient feeling of nausea.
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9 DISCUSSION
9.1 Discussion of methods
In studies I to IV, a randomized and controlled cross-over design was used to control 
problems arising from possible interindividual variations. Th is design also enabled the use 
of relatively few subjects, as each subject served as his own control. Only healthy young 
adult male volunteers were studied. Female volunteers were excluded because of fear of 
hormonal disturbances in drug pharmacodynamics. It should also be noted that these results 
may not be applicable in elderly patients, patients with other hemodynamic or respiratory 
compromises, or patients with concomitant use of other respiratory depressant drugs. 
9.1.1 Accuracy of respiratory inductive plethysmography
Th e respiratory inductive plethysmography used in this study has been found to be accurate 
(Watson et al 1988, Sackner et al 1989, Valta et al 1992, Leino et al 2001). Th e calibration of 
RIP was done semiquantitatively according to the method described by Sackner (1989) and 
Leino (2001). Th is calibration method is carried out during a brief period of natural breath-
ing subjects lying in supine position. If a known volume reference, i.e. pneumotachometer, 
is not used for volume calibration as done in studies II,III, V, the relative changes in VT and 
its derivatives VE and VT/TI can still be tracked (Sackner et al 1989). Th e validity of this 
calibration method and the analysis of VT is reported to be stable even for long follow-up 
periods (Valta et al 1992, Leino et al 2001).
Th ere are some factors aff ecting the accuracy of RIP. First, the validity of VT measurements 
declines with very high or low VT (Sackner et al 1989). In the present set of studies, very 
low VT-values were not seen and the high VT-values obtained were within 145% of the 
calibration values (I,II,IV), therefore the validity of VT should be appropriate. Secondly, 
RIP measurements of ribcage volume (RC%) displacement can overestimate the actual 
displacement during quiet breathing. Th is is due to the fact that signifi cant portion of the 
total thoracic volume change during inspiration does not displace gas but accommodates a 
substantial increase in intrathoracic volume. It is also due to the fact that the lower part of 
the ribcage is not in contact with the lungs but forms part of the abdominal cavity and the 
motion of this area does not contribute to the changes in lung volume (Warner et al 1995). 
However RIP was considered by Warner (1995) to be a valid tool to measure anesthetic 
eff ects on chest wall motion, if not the actual displacement of chest wall structures. In the 
present set of studies, RC% was studied in conjunction with escalating plasma alfentanil 
and fentanyl concentrations (IV) and the value was used for detecting chest wall rigidity, 
i.e. decreased RC%. However, in study IV, RC% increased dose-dependently from the 
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baseline values, and the possibility of chest wall rigidity was therefore excluded. Th irdly, 
if the subjects position is changed other than horizontally during the RIP measurement, 
the changes in VT may be rendered inaccurate (Warner et al 1995). Th is was prevented 
during the present studies by asking the volunteers (I–IV) and patients (V) to lie still 
during the experiment. 
9.1.2 Accuracy of indirect calorimetry
Indirect open calorimetry is designed for both spontaneously breathing and mechanically 
ventilated patients. Th e validation of this method was done by Takala et al (1989). In canopy 
measurements the mean error is 3±2% in VCO2 and 4±2% in VO2, with the range of VO2 
and VCO2 being from 100 to 400 ml/min. Increasing the FiO2 resulted in increasing error 
of VO2, with values of >0.8 being invalid. Th is error was prevented by keeping the FiO2 at 
0.21 (studies I–IV). Rising VE reduces the accuracy only slightly. In the study of Takala et al 
(1989), VO2 measured by indirect calorimetry was consistently larger than VO2 measured by 
the Fick’s principle. Despite this diff erence, there was a strong positive correlation between 
the two methods. In two other studies, the mean error for measurement of VCO2 ranged 
from 1.5% to 7% and for VO2 1.9% to 7% (Phang et al 1990, Weissman et al 1984).  Th e 
risk of errors caused by leaks during the canopy measurement is relatively small since air 
is sucked through the canopy. In studies I,III and IV, indirect calorimetry was mostly used 
for the measurement of mean drug-induced changes in VO2 and VCO2. 
Changes in ventilatory pattern or cardiac output may lead to a new equilibrium in the body’s 
O2 and CO2 stores. Both opioid-induced apnea or hypoventilation as well as drug-induced 
hemodynamic alteration may aff ect the measurements of VCO2 and VO2. Th e eff ect of this 
fl uctuation can be minimized by prolonging the measurement period. A decrease in VE may 
cause a change in body CO2 pool and decrease VCO2, which does not necessarily refl ect 
a decrease in metabolic VCO2. However, in addition to decreasing VE, opioids could also 
decrease the metabolic component of VCO2. In studies I,III and IV, baseline measurement 
were performed aft er a15 to 20-minute stabilization period. Th e duration of other measure-
ment periods was limited by shortness of opioid-induced changes in ventilation. However, 
at least 3 values, each sampled during a one minute period, were used for determination 
of VO2 and VCO2 during the studies.
Alveolar ventilation in studies I, III and IV was determined from the formula VA=0.115xVCO2/
PaCO2 (Tulla et al 1995). Calculating alveolar ventilation from PaCO2 gives an estimate of 
the physiological dead space and this form of calculation has been validated by Kiiski et 
al (1991), especially when measuring the relative changes in alveolar ventilation as done 
in studies I, III and IV.
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9.1.3 Reliability of pharmacodynamic modeling
In study IV, pharmacodynamic modeling was performed in order to evaluate the potency 
ratio for respiratory depression of alfentanil and fentanyl. In the model used in study IV, 
the rise in PaCO2 and decrease in PaO2 was not taken in to account. Th us the apparent 
EC50-values were not corrected for normocapnia and may therefore be biased (Bouillon 
et al 1999, Glass et al 1999). However, the pharmacodynamic modeling was performed in 
order to calculate the potency ratio of respiratory depression, and the EC50 values obtained 
in study IV were therefore called “apparent” values.
9.1.4 Suitability of methods used
In the present series of studies a non-invasive monitoring system was used for ventila-
tory measurements. Th is was done to avoid the possible problems associated with the 
use of nose-clips and facemasks, which are mandatory if methods such as spirometry or 
ventilatory challenges are used. Nose-clips and facemasks are shown to induce changes 
in breathing pattern: VT decreases and respiratory rate increases with varying results to 
VE and VT/TI, if such devices are used (Gilbert et al 1972, Weissmann et al 1984, Han et 
al 1997). Th ese changes in ventilation have been attributed to irritation and stimulation 
of nasal mucosa (Gilbert et al 1972) or the possibility that the process of registration itself 
draws the subject’s attention to his own breathing (Han et al 1997). Th e classical method 
to study the opioid-induced changes in ventilation is to use ventilatory challenges, mainly 
ventilatory response to CO2. Th ese tests are valid to represent the single most important 
mechanism in ventilatory control. However, there are some problems associated with the 
ventilatory challenge to CO2. Firstly, there are diff erences in response to endogenous and 
exogenous CO2 loading in vivo. Secondly, extrapolation of the linear VE/PaCO2 back to 
zero VE is not without problems (Dempsey 1976). Th irdly, increased FiCO2 also increases 
cardiac index, HR and peripheral blood fl ow, which makes simultaneous hemodynamic 
measurements unreliable (Cullen et al 1974, Braune et al 1997). Th e increasing hypercapnia 
during the challenges may also cause increases in ventilation by behavioral infl uences to 
minimize unpleasant breathing sensation, not only autonomic respiratory control (Oku et 
al 1966). Furthermore, there is a wide variability in the slope of ventilatory response to CO2 
between individuals and it is recommended that rebreathing tests should not be repeated 
more frequently than once every 15 minutes (Jordan 1982, Blouin et al 1996). 
Using the method of resting ventilation was also done to mimic a true clinical situation 
without any artifi cial stimulants or disturbances. While the subjects were breathing room air 
(I–IV), developing hypoxia and/or hypercapnia could possibly have stimulated ventilation, 
making the subjects tolerate higher opioid doses than expected. Th is was most evident with 
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long opioid infusions (II,IV). Th erefore the study setting was not thoroughly controlled, 
but this was unavoidable with this form of monitoring system. 
Upper airway obstruction could also contribute to ventilatory depression induced by 
opioids. In the present sets of studies this did not occur, evidenced by non-paradoxal chest 
movement monitored with RIP.
Th e pain stimulation used in the present set of studies (II, III) consisted of upper arm 
tourniquet. Th is stimulus was not suffi  cient enough to induce any increases in plasma 
catecholamine concentrations. In study III, MAP was increased because of the pain stimu-
lus, but HR was not aff ected in either of the studies. Th e pain stimulus is thus considered 
rather weak. However, in study III it helped to diff erentiate the hemodynamic eff ects of 
morphine and oxycodone.
9.2 Discussion of the results
9.2.1 Respiratory effects
Pain is a considerable respiratory stimulant and counteracts the respiratory depression 
induced by opioids. However, a moderate or severe respiratory depression may occur 
despite lack of analgesia as shown by Dahan et al (2004) who quantifi ed analgesia and 
respiratory depression in healthy volunteers who were given morphine 0.2 mg/kg. In the 
present set of studies the peak eff ect of morphine-induced decrease in alveolar ventilation 
occurred at 10 to 15 minutes aft er intravenous injection (III). Th is is well in accordance 
to previous data, where the clinical eff ects of morphine only occur aft er a certain time lag 
(Hamunen 1993, Orkin et al 1955). Th e respiratory depression noted aft er morphine 0.07 
mg/kg and 0.14 mg/kg was modest: both PaO2 and PaCO2 were maintained within normal 
limits. Respiratory rate was only slightly decreased aft er the higher morphine dose, 0.14 
mg/kg, whereas 0.07 mg/kg did not aff ect respiratory rate. Th is decrease in respiratory rate 
has been previously reported aft er morphine administration (Rigg et al 1981, Samuel et al 
1977). Th e slight decrease in VA and respiratory rate did not aff ect arterial oxyhemoglobin 
saturation or carbon dioxide elimination in a clinically signifi cant manner and could thus 
be considered as minor changes. 
Oxycodone 0.14 mg/kg given to healthy volunteers (III) aff ected respiration more pro-
foundly than morphine using the same dose. Respiratory rate and VA were decreased, peak-
ing at 4 to 10 minutes, which is slightly earlier compared to morphine. Th is is in accordance 
to previous studies, where the onset of analgesia and respiratory depression occurs earlier 
with oxycodone than morphine (Kalso et al 1991, Olkkola et al 1994). However, if a similar 
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dose of oxycodone, 0.14 mg/kg is given to trauma patients with severe pain, respiration is 
not aff ected (V). Th is is in accordance to the study of Galinski et al (2005), where morphine 
0.1 mg/kg was given as an analgesic for prehospital pain and no eff ects in respiration were 
detected. Th e patients in study V were previously healthy and no other medication was 
given in conjunction with the opioid. Th is elucidates the importance of not applying the 
results obtained from postoperative patients or healthy volunteers directly to patients with 
severe, acute pain. Especially patients with acute fractures appears to receive insuffi  cient 
doses of analgesics (Lewis et al 1994, Goodacre et al 1996, Jones et al 1996). Even though 
the potency ratio of morphine and oxycodone was not investigated in the present set of 
studies, the deeper respiratory depression induced by oxycodone administration suggests 
that oxycodone is more potent than morphine, as earlier evidenced by Kalso et al (1991). 
Even though morphine has higher binding affi  nity to μ-receptor, the higher blood-brain 
barrier penetration of oxycodone versus morphine could off er an explanation for this 
(Lalovic et al 2006).
A bolus dose of 112.5 mg pethidine aff ected respiration transiently (II). Th e respiratory 
rate was not aff ected, but VT decreased, resulting in a decrease in SpO2 to low normal 
limits. Th is eff ect had already vanished at 30 minutes post injection. Th ese fi ndings are in 
conjunction with the study of Orkin et al (1955), in which 100 mg an intravenous bolus 
dose of pethidine given to healthy volunteers markedly decreased VT, which returned near 
to normal within 15 minutes. Th e respiratory rate did not fall aft er the pethidine bolus. In 
a study of Tarkkila et al (1998), a bolus dose of pethidine 0.6 mg/kg was given to intubated 
patients breathing halothane in 70% nitrous oxide and oxygen. 0.6mg/kg of pethidine 
decreased both respiratory rate and VT. Th e decrease in respiratory rate can be explained 
by the simultaneous use of nitrous oxide and halothane. When 187.5 mg of pethidine was 
given as a 3-hour infusion, the opposite eff ect occurred, VT increased and respiratory rate 
decreased with little eff ect on SpO2. In previous literature both kinds of eff ects have been 
documented, the net result being a slight respiratory depression. VT/TI, an indicator of 
respiratory drive (Orkin et al 1955) was increased during pethidine infusion. Th is could 
be a result of a rise in PaCO2, which stimulates ventilation. Pethidine is documented to 
decrease ventilatory drive, which did occur aft er bolus dose of pethidine, but not during 
the 3-hours infusion (Kryger et al 1976). 
A bolus dose of 2 μg/kg fentanyl decreased VE by decreasing respiratory rate, whereas VT 
was concomitantly increased (I). Th e peak eff ect of this occurred within 5 minutes aft er 
the injection and lasted approximately 30 minutes. Th e timing of respiratory depression 
is consistent with previous literature where the time to peak eff ect is described to occur 
within 3.6 to 4.5 minutes (Scott et al 1985, Ebling et al 1990, Scholz et al 1996). However, 
longer time lag for peak eff ect has also been documented (Kaufman et al 1979). In the 
study of McClain et al (1980), a fentanyl bolus 3.2–6.4 μg/kg  decreased respiratory rate 
markedly, but nearly normal values were already obtained in 15 minutes aft er the injection. 
When fentanyl was given as a long-lasting, computer-controlled infusion with escalating 
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plasma fentanyl concentrations, a signifi cant change in respiratory variables occurred at 
plasma concentrations between 0.25–2.5 ng/ml (IV). VT was increased and respiratory 
rate decreased similarly as with the bolus injection of fentanyl (II). However, the subjects 
were still breathing at plasma concentrations of 4.0 ng/ml. Th is plasma concentration is 
surprisingly high compared to many of those of previous studies, where the threshold 
of spontaneous ventilation is described to be as low as 1.5 ng/ml (Andrews et al 1983, 
Cartwright et al 1983, Clotz et al 1991, Shafer et al 1991). Th ere could be several reasons 
explaining this. Along the infusion, hypoxia and hypercarbia were developed. Th ese both 
act as potent respiratory stimulants and counteract the respiratory depression induced by 
fentanyl. Th is is supported by preserved VT/TI, which suggests well maintained respiratory 
drive. Also, acute opioid tolerance might develop during the opioid infusion (Guignard 
et al 2000, Scamman et al 1984). Recently, a mathematical model for fentanyl-induced 
respiratory depression was introduced by Magosso et al (2004). In this model, previous 
literature (including study IV) of respiratory depression caused by fentanyl was taken into 
account and a mathematical model describing this phenomenon was produced. In this 
model, the eff ect of fentanyl on ventilatory control has been mimicked by multiplying the 
peripheral and central chemoreceptor gain by an attenuation factor, which depends on 
opioid plasma concentration.
Th e eff ects of alfentanil infusion, given as computer-controlled infusion with escalating 
plasma alfentanil concentrations, closely resembled those of fentanyl (IV). A signifi cant 
respiratory depression was noted at plasma concentrations between 12.5–125 ng/ml. Th e 
volunteers were still breathing at plasma levels of 200 ng/ml. Recovery of spontaneous 
ventilation aft er surgery is reported to occur with plasma concentrations of 125 to 226 
ng/ml (Ausems et al 1988, Clotz et al 1991, Shafer et al 1991). Th e same reasons explaining 
spontaneous ventilation with high plasma concentrations of fentanyl are also applicable to 
alfentanil. Muscle rigidity has been postulated to be one of factors contributing to alfentanil 
induced respiratory depression. No muscle rigidity was seen during alfentanil infusion, 
as evidenced by increasing RC%, despite high plasma concentrations. Previous literature 
mostly connects the alfentanil-induced rigidity to rapid injection, but muscle rigidity is 
also seen during infusions (Benthuysen et al 1986).  
If the respiratory eff ects of alfentanil and fentanyl are compared during the infusions, no 
major diff erences can be found. Only VA and SpO2 decreased sooner with fentanyl, all other 
variables showed similar time course. In previous literature the respiratory depression is 
described to be similar with alfentanil and fentanyl (Hill et al 1990), but alfentanil has 
also been suggested to cause less respiratory depression (Andrews et al 1983, Scamman 
et al 1984, White et al 1986). Th e changes in breathing pattern were similar to those seen 
in study II with pethidine infusion (Table 4). Also, in the studies of Persson et al (1999) 
and Leino et al (1999), a long infusion of opioid decreases respiratory rate and the timing 
of respiration, while respiratory drive is either increased or not aff ected at all. Opposite 
results have also been found, though (Cartwright et al 1998). In the study of Bouillon et al 
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(2003), alfentanil caused a decrease in VE and increased the variation of VT, i.e. disturbed 
the regularity of breathing. Th e potency-ratio of alfentanil and fentanyl induced respira-
tory depression (1:39–1:51) was calculated in study IV to be similar to analgesic potency 
ratio or slowing of EEG studied elsewhere (Scott et al 1985, 1987, Hill et al 1990, Glass et 
al 1993, Westmoreland et al 1994, Gambus et al 1995). 
Th e respiratory depression caused by tramadol was minimal (II). Both VT and respiratory 
rate were preserved aft er tramadol 150 mg bolus as well as 250 mg given as 3-hour infusion. 
SpO2 as well as PaCO2 were also maintained within normal limits throughout the study. 
Th ese fi ndings are in line with previous studies, where the respiratory eff ects of tramadol are 
found to be negligible (Radbruch et al 1996, Tarkkila et al 1998, Grond et al 2004). However, 
the total dose given in this study, 400 mg, is the daily maximum dose recommended and 
no previous study has evaluated the eff ects of this dose to respiration.
A low dose of ketamine, 0.25 mg/kg, was combined with fentanyl in order to evaluate 
whether it could counteract the opioid-induced respiratory depression. Th e respiratory 
eff ects of ketamine vary in previous literature,  from respiratory depression to respiratory 
stimulation (Hui et al 1955, Corssen et al 1966, Soliman et al 1975, Mankikian et al 1986, 
Reich et al 1989). Ketamine attenuated the decrease which fentanyl caused in VE as well 
as VA, but it did not have any eff ect on the hypoxia or hypercarbia caused by fentanyl. Th e 
increase in VO2 could at least partly explain the reason why PaO2 and SpO2 were not aff ected, 
even though ketamine was added to fentanyl. In the study of Persson et al (1999) ketamine or 
placebo was delivered with computer controlled infusion together with computer controlled 
alfentanil infusion. VE, TI/TTOT, respiratory rate and SpO2 were all elevated to baseline level 
when ketamine was added to alfentanil compared to using alfentanil alone. Th e possible 
reason for this discrepancy in results is that in the study of Persson et al (1999), both drugs 
were given as slow infusions with slowly escalating plasma drug concentrations, while in 
study I both ketamine and fentanyl were injected as a bolus, thus resulting in a very high 
plasma drug concentration. In the study of Persson et al (1999), hemodynamics were not 
aff ected by ketamine and VO2 was not measured. All these older studies were performed 
with racemic ketamine. Recently, the S (+)-enantiomer of  ketamine, i.e. S(+)-ketamine, 
has been available. S(+)-ketamine is twice as potent as the racemic mixture (Kohrs et al 
1998). In an animal model S(+)-ketamine has been shown to induce respiratory depression. 
Direct comparison of racemic and S(+)-ketamine in respect to respiratory depression has 
not been evaluated (Kohrs et al 1998, Sarton et al 2001).
As a rule, all opioids induce respiratory depression to some degree. However, there are 
aspects which need to be taken into account when comparing the results of diff erent stud-
ies. First, the mode of administration, bolus or injection aff ects the results. Slow opioid 
infusions, even with large net dosage are well tolerated in respect of respiratory depression 
(II,IV). Respiratory depression is deeper when an opioid is given as a bolus (II), this being 
due to instantly high plasma concentrations. Secondly, when comparing studies where 
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opioid-induced respiratory depression is studied, the mode of measurement needs to be 
taken into account. Diff erent results can be obtained with invasive, i.e. rebreathing, methods 
and non-invasive methods. Th irdly, the setting where the opioid is given and the use of 
concomitant depressant drugs, i.e.,  postoperatively aft er anesthesia, to patients with acute 
pain (V) or to healthy volunteers (I–IV), all aff ect the developing respiratory depression. 
Even considerably large bolus doses can be given to hemodynamically stable patients with 
acute pain without any respiratory depression (V). Th ese results may be of benefi t when 
treating patients with acute pain in emergency situations. Also, if respiratory depression 
does occur, patients are still responsive to commands and can be instructed to breathe. 
9.2.2 Hemodynamic effects
All opioids are considered to be hemodynamically stable. However, minor bradycardia, 
which cannot be considered as baroreceptor action might be evident aft er opioid adminis-
tration (Fukuda 2006). Morphine 0.07 and 0.14 mg/kg given to healthy volunteers induced 
a transient, but clear hemodynamic stimulation (III). Both doses of morphine increased 
MAP as well as HR, which phenomenon was not shown in previous human studies. Th is 
increase was very short lasting and might not be found if the time point of measurement is 
postponed for more than a few minutes aft er injection. Th e classical eff ect of morphine on 
hemodynamics in previous literature is hypotension accompanied by tachycardia (Table 2). 
However, morphine is oft en studied in conjunction with cardio depressant drugs, such as 
anesthetics or beta-blockers. According to previous animal studies, the latter combination 
abolishes the stimulatory eff ect of morphine and turns it into hypotension and tachycardia. 
(Kayaalp et al 1966, Vatner et al 1975, Wallenstein et al 1979). In the study of  Pfeiff er et 
al (1983), μ-agonists selectively injected intracerebroventricularly in rats, induce cardio-
vascular stimulation with low doses and bradycardia with high doses as well. In a recent 
study of Carter et al (2002) i.v. morphine given to healthy volunteers induced a increase in 
MAP and sympathetic nerve activity. Zelis et al (1974) have measured the forearm venous 
tone in human subjects given 15 mg iv morphine. Th e initial reaction to morphine was 
a profound venoconstriction, which subsided in 5 minutes to venodilatation. Th is initial 
vasoconstriction occurred parallel to hemodynamic stimulation in study III.
Th e hemodynamic eff ects of oxycodone 0.14 mg/ml were minimal (III). When given 
to healthy volunteers oxycodone did not aff ect HR, but a slight decrease in MAP was 
noted. When given to acutely traumatized patients, oxycodone decreased MAP slightly 
but non-signifi cantly and had no eff ect on HR (V). Th e hemodynamic eff ects of oycodone 
are very little studied, but the results of these studies verify the preliminary assumption 
of hemodynamic stability aft er oxycodone administration (Takki et al 1973, Olkkola et al 
1994). Th is gives oxycodone a certain benefi t compared to morphine.
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Pethidine-induced hemodynamic eff ects vary in diff erent studies, the typical eff ect being 
chronotropy with simultaneous hypotension (Flacke et al 1985, Takki et al 1973). In the 
study of Flacke et al (1985), 5mg/kg of pethidine caused clear tachycardia and hypotension. 
However, these patients received diazepam and droperidol prior to pethidine administra-
tion, which most likely explains the hemodynamic result. In the present set of studies when 
pethidine was given as 112.5 mg (approximately 1.5mg/kg) i.v. bolus, a slight increase in 
both HR and MAP was noted (II). Th is eff ect did not reach signifi cance though. In the 
study of Hamunen (1993), no changes in HR or MAP were noted when pethidine was 
given postoperatively to children. Also in the study of Tarkkila et al (1998), pethidine 
caused insignifi cant decrease in HR and MAP, when given in conjunction with halothane 
anesthesia. In study II, when 187.5 mg of pethidine was infused as 3-hour infusion, MAP 
remained stable, but HR was signifi cantly reduced showing a classical μ-agonist eff ect. A 
large amount of pethidine can thus be injected to previously healthy subjects without any 
signifi cant hemodynamic compromises. 
Hemodynamics has been reported to remain stable aft er both fentanyl and alfentanil 
administration (Scott et al 1985, Bailey et al 2000, Fukuda 2005). In a recent study of Lessa 
et al (2004), high doses of fentanyl given to rats seemed to be hemodynamically stable end 
even elicit signifi cant cardioprotective eff ects in a model of arrhythmia. A slight bradycardia 
is documented aft er fentanyl and alfentanil administration. When 2 μg/kg of fentanyl was 
given as a single bolus, HR was transiently decreased, whereas MAP remained at baseline 
level (I). During long, computer-controlled infusions of fentanyl and alfentanil, both 
HR and MAP remained stable (IV). Th e developing hypercarbia or hypoxia could have 
counteracted the classical μ-agonist  eff ect, bradycardia.
Tramadol did not have much eff ect on hemodynamics, both mean arterial pressure and 
heart rate were unaff ected despite a large dose of tramadol infused (II).  Th is is well in 
line with the results of previous studies (Radbruch et 1996, Tarkkila et al 1998, Grond et 
al 2004).
Th e addition of a small dose of ketamine to fentanyl, signifi cantly altered the hemodynamic 
response of fentanyl alone (I). Both MAP and HR were elevated when ketamine was used. 
Th ese eff ects of ketamine are well known from previous literature and are thought to be 
related to centrally mediated catecholamine release (Corssen et al 1966, Traber et al 1968, 
Tweed et al 1972, Ivankovich et al 1974). Even if a very small dose of ketamine was used 
and it was done in conjunction with a moderate dose of a negative chronotrop, fentanyl, 
ketamine still showed these characteristic stimulatory eff ects. In the study of Persson et al 
(1999), ketamine was given together with alfentanil as computer controlled infusions and 
no change in either MAP or HR was noted when ketamine was added to alfentanil.   
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9.2.3 Effects on gas exchange
Morphine-induced cardiovascular stimulation was accompanied by a transient increase in 
VO2 (III). Th is was clearly evident with 0.14 mg/kg of morphine and has not been reported 
in any of the previous studies. While ventilation was not increased at this time point, the 
change in VO2 is most probably due to metabolic increase in oxygen consumption.  In 
the study of Orkin et al (1955) 10 mg i.v. morphine caused a slight but no signifi cant rise 
in oxygen uptake, as calculated from the reduction in volume of spirometer drum. In the 
study of Jennet et al (1968) morphine was given as 10mg/ 70 kg i.v. bolus and VO2 was 
measured with spirometer and showed a decrease 5–10 min aft er injection. No values 
were measured immediately aft er drug injection, which is why the possible increase in 
VO2 could have been missed. Although VO2 measured with Deltatrac refl ects whole body 
VO2, the increase in HR indicates that myocardial VO2might also be transiently increased. 
However, it has been suggested that morphine might have some cardio protective action, 
which is mediated through δ-receptor (Bailey et al 2000, Kato et al 2002, Lessa et al 2004, 
Fukuda 2005). Oxycodone had no eff ect on VO2 in healthy volunteers (III). VO2 was slightly 
decreased aft er oxycodone, which probably refl ects hypoventilation. Fentanyl 2 μg/kg bolus 
decreased VO2 transiently (I), while VO2 was gradually decreased during fentanyl infusion 
with escalating plasma concentrations (IV). Both these eff ects are most probably due to 
decreased respiratory rate and hypoventilation, not necessarily true decrease in oxygen 
consumption. However, opioids might also decrease the metabolic component of VO2 by 
reducing heart rate (Bailey et al 2000, Fukuda 2005). Th e eff ect of alfentanil infusion on 
VO2 was similar to those of fentanyl. 
When a small dose of ketamine, 0.25 mg/kg, was added to fentanyl, a transient increase 
in VO2 was noted. Th is was accompanied by the hemodynamic stimulation caused by the 
drug combination. Th is increase in VO2 resulted in similarly low blood oxygenation, as 
did fentanyl alone, despite more preserved VA and VE. Th e eff ect of ketamine on VO2 has 
been well documented and is thought to be a result of increased sympathetic tone (Traber 
et al 1968, Tweed et al 1972). 
9.2.4 Effects on plasma catecholamines
Morphine did not have any clinically signifi cant eff ect on plasma catecholamine concentra-
tions. In some previous studies similar results, i.e. no signifi cant catecholamine release, were 
found aft er a high dose of morphine (Flacke et al 1985, Doenicke et al 1995). However, in 
the study of Fahmy et al (1983), 0.3 mg/kg of intravenous morphine caused a signifi cant in-
crease in plasma epinephrine concentrations. Tachycardia induced by morphine is thought 
to be a result of histamine and catecholamine release based on the observation that these 
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changes occur simultaneously (Fahmy et al 1983, Flacke et al 1987, Muldoon et al 1987). 
Th e eff ects of oxycodone on plasma catecholamines were also minimal. Epinephrine, not 
norepinephrine, concentration was elevated aft er oxycodone administration. Th is can be 
explained by mild hypoxia caused by oxycodone.  Pethidine caused a signifi cant increase 
in both epinephrine and norepinephrine concentrations. Th is has also been documented 
previously in the study of Flacke et al (1985). In study II, tramadol increased plasma 
epinephrine concentrations, but had no eff ect on norepinephrine concentrations. In the 
study of Garcia-Quetglas et al (2007), plasma epinephrine concentrations were increased 
aft er tramadol in conjunction with adverse eff ects, i.e., nausea and vomiting. Th is fi nding 
is in accordance to our results in study II. 
9.2.5 Effects on plasma histamine
Plasma histamine concentrations were maintained well under 0.4 ng/ml aft er morphine 
and oxycodone administration (III). Th e level of histamine plasma concentration to elicit 
symptoms is reported to be over 1 ng/ml, with baseline level being 0.6 ng/ml (Kaliner et al 
1982). Histamine infusion is reported to cause tachycardia and widening of pulse pressure, 
these changes being evident immediately aft er histamine release and vanishing quickly 
because of rapid clearance. (Kaliner et al 1982). In study III, the sampling for  plasma 
histamine was done simultaneously with the hemodynamic stimulation observed, which 
should have detected any changes in plasma histamine concentrations. Our results diff er 
from many previous reports concerning histamine liberation aft er morphine (Philbin et al 
1981, Rosow et al 1982, Flacke et al 1985, Moss et al 1983, Muldoon et al 1987, Withington 
et al 1993, Doenicke et al 1995). Th e study of Warner et al (1991) however gives similar 
results compared to study III, with no histamine release aft er morphine. Th eir explanation 
to their contradictory results is that they used a more novel assay of histamine detection, 
double-isotope assay, instead of single-isotope assay used in the older studies (Philbin et 
al 1981, Rosow et al 1982, Flacke et al 1985, Moss et al 1983). In the studies of Doenicke 
(1995) and Withington (1993), not all subjects produced histamine release aft er morphine 
administration. It could therefore be theoretically possible that in study III, all eight volun-
teers were unable to liberate histamine, and repeating the same study on other volunteers 
would give diff erent results.  In study III, local signs of possible histamine release were 
seen, fl are and itching was detected in all subjects aft er morphine administration. Th is local 
liberation of histamine has also been demonstrated also previously (Hermens et al 1985, 
Levy et al 1989) and is thought to originate form skin mast cells and not to be mediated 
through μ-receptor (Blunk et al 2004). Th e histamine releasing ability of oxycodone is 
thought to be minimal (Pöyhiä et al 1992) as in study III. Th is was further confi rmed by 
another study of Pöyhiä et al (2004). However, Ennis (1991) has shown that porcine mast 
cells liberate histamine aft er oxycodone administration even more than aft er morphine 
administration.
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Th e ability of opioids to induce cardiovascular changes or to liberate histamine or catecho-
lamines still remains incompletely examined and answered. Th e hemodynamic changes 
induced by opioids seem to be infl uenced by the dose of opioid, the mode of administration, 
i.e. bolus injection or slow infusion and possible concomitant medication. High plasma 
concentrations in conjunction with bolus dosing produce clearer hemodynamic changes 
than slowly escalating plasma concentrations with infusions. If  hemodynamic eff ects are 
studied on patients with beta-blocking agents or vasodilatators such as droperidol, the net 
eff ect is naturally diff erent. Th e diff erent results with catecholamine and histamine release 
in this study compared to previous studies are more diffi  cult to explain than the diff erent 
result in hemodynamic profi le. Th e capacity of morphine and pethidine to release hista-
mine or catecholamine is probably not as straightforward. Th ere might be subjects with 
more easily provoked histamine release, or some histamine assays might be more reliable 
than others. However, in the case of the present study, the truth about catecholamine and 
histamine release aft er opioid administration still remains unsettled.
9.2.6 Effects on atelectasis formation
No atelectasis formation was seen in any of the extremity trauma patients treated with 
oxycodone (V). In previous studies atelectasis formation and low lung volumes were seen 
in patients treated with respiratory depressant drugs while breathing oxygen enriched air 
(Rothen et al 1995, Reber et al 1996). Increased atelectasis formation is already seen with 
30% oxygen, but the atelectasis formation is greater with increasing oxygen concentra-
tion, being most evident with 100% oxygen (Nunn et al 1978, Rothen et al 1995). Th is is 
considered to be associated with decreased VT. In study V, VT were not decreased con-
siderably and the inspired oxygen concentration was chosen to be 40%, not higher. Th ese 
factors can contribute to the fact that no atelectasis was seen in any of the patients. In the 
previous studies where atelectasis was seen, it caused some degree of hypoxia despite the 
supplemental oxygen (Mackersie et al 1991, Rothen et al 1995). All our patients breath-
ing 40% oxygen had oxygenation values well above normal, supporting the conclusion of 
normal lung function. 
9.2.7 Limitations of the present series of studies
Th e results of the current series of studies must be interpreted with caution due to some 
experimental limitations. Healthy volunteers were used in studies I–IV. Th e results must 
therefore be carefully extrapolated to patients with underlying diseases or hemodynamic 
compromises. Patients with cardiovascular diseases, especially those using heart rate 
regulating drugs, could present diff erent hemodynamic profi le aft er opioid administra-
tion. Also, if hepatic or renal function is compromised, the pharmacokinetic and thus also 
pharmacodynamic profi les of opioids could be greatly altered. Patients with diabetes oft en 
58 DISCUSSION
have impaired peripheral neuronal control and could also react diff erently to these drugs. 
Th e ventilatory eff ects of opioids could also be diff erent in patients with pulmonary disease. 
And as mentioned before, O2 administration could also have an impact on the respiratory 
eff ects of opioids.  In studies I–IV each volunteer served as his own control, which allows 
the use of a smaller number of subjects. In study V, a relatively small number of patients 
(13) were studied, which might increase the risk of error of the results. 
Th e visible respiratory depression and sedation might have obscured the double-blindness 
in study III, where placebo was used. 
Th e magnitude of the norepinephrine release in studies II and III may not be refl ected 
exactly in the concentrations from arterial blood samples. Compared to arterial blood, 
venous blood has been shown to contain higher concentrations of norepinephrine. 
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10  SUMMARY AND CONCLUSIONS
Th is study was performed in healthy volunteers (I–IV) and trauma patients (V). Th e 
opioids studied were fentanyl, alfentanil, morphine, oxycodone, pethidine and tramadol. 
Furthermore, ketamine was studied in conjunction with fentanyl. Non-invasive ventila-
tory measurements (RIP, indirect calorimetry) were used in order to avoid the problems 
depicted with respiratory challenges.
Th e following main conclusions can be drawn:
-  All opioids studied caused a decrease in respiratory parameters. Respiratory rate, VA and 
VE decreased (I–IV), while VT increased in most situations, except during tramadol-infu-
sion and aft er bolus dose of pethidine, where it decreased (I). Th e respiratory depression 
caused by 0.14 mg/kg of oxycodone was deeper than the one caused by the same dose of 
morphine (III). Breathing pattern was also signifi cantly aff ected aft er opioid adminis-
tration (II,IV). An equianalgesic dose of tramadol caused markedly smaller respiratory 
depression compared to pethidine, when given as a iv-bolus and 3-hour iv-infusion.
-  Th e potency ratio for respiratory depression of fentanyl and alfentanil varied from 
1:39–1:51, which is similar to the analgesic potency ratio studied elsewhere.
-  0.25 mg/kg of racemic ketamine attenuated the respiratory depression caused by 2 μg/kg 
fentanyl. However, this occurred at the expense of increased VO2, which resulted in 
unchanged levels of PaO2 and SpO2.
-  Intravenous morphine caused a transient hemodynamic stimulation, which was accom-
panied by increase in VO2. Th is phenomenon was not noted with the use of intravenous 
oxycodone. Alfentanil, fentanyl, tramadol and pethidine infusion had minimal eff ects 
on hemodynamics.
-  Plasma catecholamine concentrations were increased aft er morphine, oxycodone, pethi-
dine and tramadol administration. However, plasma histamine concentration was not 
elevated aft er morphine administration. Oxycodone did not aff ect plasma histamine 
level, and plasma epinephrine level was increased in conjunction with hypoxia.
-  Supplemental oxygen did not cause any atelectasis when given to opioid treated trauma 
patients. However, patients breathing room air had a suffi  cient level of oxygenation, so 
supplemental oxygen did not add any benefi ts  to these patients.
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